Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2023 Oct 13;20(10):e1004299. doi: 10.1371/journal.pmed.1004299

Risk factors for extended-spectrum beta-lactamase (ESBL)-producing E. coli carriage among children in a food animal-producing region of Ecuador: A repeated measures observational study

Heather K Amato 1,*, Fernanda Loayza 2, Liseth Salinas 2, Diana Paredes 2, Daniela Garcia 2, Soledad Sarzosa 2, Carlos Saraiva-Garcia 2, Timothy J Johnson 3,4, Amy J Pickering 5,6, Lee W Riley 7, Gabriel Trueba 2, Jay P Graham 1,*
PMCID: PMC10621961  PMID: 37831716

Abstract

Background

The spread of antibiotic-resistant bacteria may be driven by human–animal–environment interactions, especially in regions with limited restrictions on antibiotic use, widespread food animal production, and free-roaming domestic animals. In this study, we aimed to identify risk factors related to commercial food animal production, small-scale or “backyard” food animal production, domestic animal ownership, and practices related to animal handling, waste disposal, and antibiotic use in Ecuadorian communities.

Methods and findings

We conducted a repeated measures study from 2018 to 2021 in 7 semirural parishes of Quito, Ecuador to identify determinants of third-generation cephalosporin-resistant E. coli (3GCR-EC) and extended-spectrum beta-lactamase E. coli (ESBL-EC) in children. We collected 1,699 fecal samples from 600 children and 1,871 domestic animal fecal samples from 376 of the same households at up to 5 time points per household over the 3-year study period. We used multivariable log-binomial regression models to estimate relative risks (RR) of 3GCR-EC and ESBL-EC carriage, adjusting for child sex and age, caregiver education, household wealth, and recent child antibiotic use. Risk factors for 3GCR-EC included living within 5 km of more than 5 commercial food animal operations (RR: 1.26; 95% confidence interval (CI): 1.10, 1.45; p-value: 0.001), household pig ownership (RR: 1.23; 95% CI: 1.02, 1.48; p-value: 0.030) and child pet contact (RR: 1.23; 95% CI: 1.09, 1.39; p-value: 0.001). Risk factors for ESBL-EC were dog ownership (RR: 1.35; 95% CI: 1.00, 1.83; p-value: 0.053), child pet contact (RR: 1.54; 95% CI: 1.10, 2.16; p-value: 0.012), and placing animal feces on household land/crops (RR: 1.63; 95% CI: 1.09, 2.46; p-value: 0.019). The primary limitations of this study are the use of proxy and self-reported exposure measures and the use of a single beta-lactamase drug (ceftazidime with clavulanic acid) in combination disk diffusion tests for ESBL confirmation, potentially underestimating phenotypic ESBL production among cephalosporin-resistant E. coli isolates. To improve ESBL determination, it is recommended to use 2 combination disk diffusion tests (ceftazidime with clavulanic acid and cefotaxime with clavulanic acid) for ESBL confirmatory testing. Future studies should also characterize transmission pathways by assessing antibiotic resistance in commercial food animals and environmental reservoirs.

Conclusions

In this study, we observed an increase in enteric colonization of antibiotic-resistant bacteria among children with exposures to domestic animals and their waste in the household environment and children living in areas with a higher density of commercial food animal production operations.


In a repeated-measures study conducted between 2018-2021 in 7 semi-rural parishes of Quito, Ecuador, Heather Kathleen Amato and colleagues aim to identify determinants of antibiotic resistant E.coli infection in children.

Author summary

Why was this study done?

  • An estimated 1.27 million deaths in 2019 were attributable to bacterial antibiotic-resistant infections, 89% of which occurred in low- and middle-income countries (LMICs).

  • Small-scale and commercial-scale food animal production is expanding rapidly in middle-income countries like Ecuador and antibiotic use in food animals is increasing at the fastest rate in these settings, fueling the emergence and selection of multidrug-resistant bacteria.

  • Evidence is needed to inform action against the spread of antibiotic resistance in communities with varying degrees of both small-scale or “backyard” and commercial food animal production, especially in South America where research on community-acquired antibiotic resistance is lacking.

What did the researchers do and find?

  • We conducted a repeated measures study in a food animal-producing region in Ecuador to compare the risk of antibiotic-resistant bacterial (ARB) carriage among children with varying degrees of exposure to backyard and commercial food animals.

  • We used multivariable log-binomial regression models to estimate relative risks (RR) of ARB carriage, adjusting for child sex and age, caregiver education, household wealth, and recent child antibiotic use.

  • Living within 5 km of >5 commercial food animal operations, household pig or dog ownership, child contact with pets, and placing animal feces on household crops were identified as significant risk factors for ARB carriage in children.

What do these findings mean?

  • This study underscores the need for improved waste management and surveillance of antibiotic resistance in LMICs with widespread food animal production.

  • A significant challenge remains: There is a lack of available data on antibiotic usage and resistance in commercial food animal operations and their effluent, in Ecuador and globally, due to limited oversight and surveillance.

  • In future studies, researchers should work with local and national governments to monitor antibiotic use and resistance in food animals, food animal production waste, nearby environmental reservoirs, and food animal products in order to more accurately characterize sources of exposure and transmission routes of community-acquired ARB.

  • The primary limitations of this study are the use of proxy and self-reported exposure measures and the use of a single beta-lactamase drug (ceftazidime with clavulanic acid) in combination disk diffusion tests for ESBL confirmation, potentially underestimating phenotypic ESBL production among cephalosporin-resistant E. coli isolates.

Introduction

Environmental fecal contamination from food animal production is increasingly recognized as an important contributor to the global antibiotic resistance crisis. Globally, large quantities of clinically important antibiotics are administered to food animals (poultry and livestock raised for meat and dairy products) to promote growth and prevent infection [1]. An estimated 1.27 million deaths in 2019 were attributable to bacterial antibiotic-resistant infections, 89% of which occurred in low- and middle-income countries (LMICs) [2]. Antibiotic-resistant bacteria, including extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), found in humans have been linked to food animals [3,4]. ESBL-E—deemed a serious threat to global public health by the World Health Organization and the US Centers for Disease Control and Prevention—confer resistance to a broad spectrum of beta-lactam antibiotics including penicillins and cephalosporins, the most commonly used treatments for bacterial infections [5,6].

With the rapid expansion of food animal production in LMICs, antibiotic use in these settings is projected to increase by upwards of 200% from 2010 to 2030, fueling the emergence and selection of these multidrug-resistant bacteria [1]. Estimating the risks of ESBL-E colonization in LMIC communities with exposures to food animal production is a crucial step towards developing strategies to combat the global spread of antibiotic-resistant bacteria. With limited treatment options, cephalosporin-resistant and ESBL-producing bacterial infections result in longer and more costly hospital stays, increased severity of illness, and increased risk of mortality [710]. Asymptomatic carriage of ESBL-E in commensal gut bacteria may still pose a threat to health; ESBLs are frequently encoded by plasmids that facilitate horizontal transfer of resistance genes, allowing commensal bacteria to share ESBL-encoded genes with pathogenic bacteria [1114]. Horizontal gene transfer rapidly propagates phenotypic resistance among diverse bacteria in animals, the environment, and humans [11,15]. Globally, the prevalence of ESBL-E is increasing; as of 2018, an estimated 20% of healthy individuals harbor ESBL-producing Escherichia coli in their guts [16].

In upper middle-income countries like Ecuador, both commercial and small-scale or “backyard” food animal production are increasing as population growth and increasing wealth drive consumption of animal products [17]. Antibiotics are largely unregulated in Ecuador and other LMICs; medically important antibiotics are routinely used in both large-scale and small-scale food animal operations at subtherapeutic doses for growth promotion and disease prevention [18,19]. In Ecuador, an estimated 84% of rural households and 29% of urban households own livestock, and small-scale poultry farmers have reported regularly administering a range of 6 different classes of antibiotics [20,21]. Contact with animal waste is elevated in LMICs, increasing the potential for exposure to ESBL-E and other antibiotic-resistant bacteria. Domestic animals and backyard food animals commonly defecate in the household environment [22,23], and young children are frequently exposed to high doses of poultry, livestock, and domestic animal feces through the consumption of soil and hand-to-mouth behaviors [24,25]. Domestic animals and fecal contamination of household soil, food, and drinking water are common sources of resistant bacteria in LMICs [2629]. Exposure to animal feces can also increase the risk of diarrhea [3032]. Epidemiological studies in LMICs have focused on exposures to feces or fecal pathogens, broadly; few studies have assessed exposures and risk factors for antibiotic-resistant and ESBL-E infections among children in LMICs [3336].

Given the anticipated growth in unrestricted antibiotic use for food animals in LMICs, there is an urgent need to quantify the risks of antibiotic-resistant and ESBL-E carriage and infections among children living near small-scale and/or commercial food animal production in these settings. This study aimed to estimate the risk of cephalosporin-resistant and ESBL-producing E. coli carriage among children with varying degrees of exposure to small-scale and/or commercial food animal production in semirural parishes of Quito, Ecuador. We hypothesized a priori that (1) household-level exposures to small-scale food animal production are associated with an increased risk of third-generation cephalosporin-resistant E. coli (3GCR-EC) and ESBL-producing E. coli (ESBL-EC); (2) exposures to commercial food animal production operations in the community are associated with an increased risk of 3GCR-EC and ESBL-EC; and (3) combined exposures to both small-scale and commercial food animal production are associated with a greater increased risk of 3GCR-EC and ESBL-EC in children than small-scale or commercial food animal exposures, alone.

Methods

Ethics statement

This study was approved by the Office for Protection of Human Subjects at the University of California, Berkeley (IRB# 2019-02-11803), the Bioethics Committee at the Universidad San Francisco de Quito (#2017-178M), and the Ecuadorian Health Ministry (#MSPCURI000243-3). Formal written consent was obtained from each primary caregiver of children enrolled in the study prior to participation.

Study site

This study was carried out in semirural communities east of Quito, Ecuador by researchers at the Instituto de Microbiología at the Universidad San Francisco de Quito (USFQ) and the University of California, Berkeley School of Public Health. The study area was approximately 320 km2 and included commercial food animal operations and small-scale or “backyard” production of food animals for both subsistence farming and trade. Irrigation canals fed by nearby rivers flow throughout communities in the study area and are used for subsistence farming and small-scale agricultural production.

Study design

This repeated measures observational study aimed to enroll 360 households through stratified random sampling across 7 semirural parishes. For power calculations and sample size determination, please see SI (Sample Size and Power Calculations in S1 Files). Random sampling was stratified at the neighborhood level (within parishes) based on the following strata, as determined by community-based fieldworkers: (1) backyard food animal production present in neighborhood; (2) backyard food animal production present and commercial food animal production within 1 km of neighborhood; and (3) no backyard food animal production and no commercial production within 1 km. Households were enrolled if they met the following inclusion criteria at the time of enrollment: (1) a primary child caretaker who was over 18 years of age was present; and (2) a child between the ages of 6 months and 5 years old was present in the household. Informed written consent was provided by the child’s caretaker prior to participation in the study. If there was more than 1 child at a given household, the youngest child was selected for participation. Due to high rates of migration out of the study site and loss to follow-up after the onset of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, we enrolled new households each cycle. Households were visited up to 5 times between August 2018 and August 2021 by trained field staff who conducted household surveys and collected household GPS coordinates and biological samples at each visit. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (Supporting information (SI), Checklist in S1 Files). Analysis plans for this manuscript were developed beginning in May 2020 and were last revised in March 2021 after sequencing results became available; we amended our analysis plan to include descriptive results of antibiotic resistance genes (ARGs) identified from sequenced E. coli isolates. This research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award Number R01AI135118.

Exposure assessment

The primary exposures of interest were exposures to commercial food animal production in the community and household-level exposures to small-scale food animal production. Exposures and other household characteristics and practices were assessed at each household visit to capture time-varying exposures. Exposure to commercial food animal production was assessed in 3 ways: (1) distance to the nearest commercial food animal production facility; (2) density of commercial food animal production facilities; and (3) proximity to drainage paths of commercial food animal production facilities. Commercial poultry production facilities—vertically integrated operations marked by long barns with a metal roof that typically held approximately 20,000 birds or more—were located using satellite imagery in Google Maps and confirmed as active operations through site visits and ground-truthing. Other types of food animal production operations were identified through local knowledge and ground-truthing.

For the first measure of commercial food animal production exposure, Euclidean distance between each household and the nearest active commercial food animal operation was measured at each time point. For the second measure of exposure, the density of commercial food animal operations was assessed by summing the number of operations within a five-kilometer buffer of each household at each time point. We used the sf package in R to create these first 2 exposure variables [37,38]. While proximity may serve as a proxy for the likelihood of environmental contamination from nearby commercial operations, density may serve as a proxy for the extent of environmental contamination from nearby operations. Density of commercial poultry operations has been associated with cephalosporin-resistant E. coli in nearby stream water and sediment in the United States [39]. Finally, for the third exposure measure, drainage paths from each commercial food animal operation were identified using ArcGIS Online Trace Downstream tool, which uses a digital elevation model to identify downstream flow paths from elevation surfaces, drainage directions, river networks, and watershed boundaries obtained from the HydroSHEDS 90 m database [40]. We then created buffers around drainage paths, which ranged from 2.9 to 3.1 km in length, and spatially joined study households to buffer layers in QGIS to identify which households were within 100 or 500 meters of commercial operation drainage paths [41] (Fig 1). Proximity to these drainage paths may capture exposures to antibiotic-resistant bacteria transported from commercial food animal operations through waterways, even when households are located further from the food animal operation, itself.

Fig 1. Map of active commercial food animal production operations (n = 130) and their drainage flow paths in the study area, east of Quito, Ecuador.

Fig 1

The inset is an aerial photograph of commercial poultry production facilities in the study area (image credit: Jay P. Graham). Map created in QGIS; contains information from OpenStreetMap and OpenStreetMap Foundation, which is made available under the Open Database License.

Household-level exposure to small-scale food animal production was defined as household ownership of any food animals (i.e., chickens, pigs, cattle, sheep, goats, ducks, guinea pigs, rabbits, or quail). Household surveys captured information on caregiver-reported household ownership of food animals and other domestic animals, as well as household characteristics, caregiver and child demographics, health status, and other potential risk factors. Surveys were created using Open Data Kit (ODK) Build and trained enumerators used ODK Collect on Android devices for mobile data collection [42]. Encrypted survey forms were sent to ODK Aggregate on a secure server at USFQ upon completion and were subsequently downloaded for de-identification and analysis.

Outcome assessment

A single stool sample from the youngest eligible child per household was collected at each visit to determine enteric carriage of 3GCR-EC and ESBL production based on phenotypic testing, described below. Caregivers were given supplies to collect a child stool sample, which were double-bagged and stored in a fridge or on ice (4°C), and the enumerator returned to collect the sample the next day. In the case that a child had not defecated before the enumerator returned, the enumerator came back to the household the following day to collect the sample. If domestic or food animals were present at the household at the time of data collection, a single stool sample per animal species was collected from the environment where the animals defecate. Fecal samples were placed in sterile containers and stored on ice (4°C) during transportation to the microbiology lab at USFQ. Samples were processed at USFQ within 5 h of collection to identify 3GCR-EC and conduct antibiotic susceptibility testing.

Microbiological methods

To screen for 3GCR-EC and improve sensitivity for detecting ESBL production among both dominant and nondominant strains of E. coli, fecal samples were plated on MacConkey agar (Difco, Sparks, Maryland) with 2 mg/L of ceftriaxone and incubated for 18 h at 37°C [43]. Up to 5 ceftriaxone-resistant isolates phenotypically matching E. coli were selected from each fecal sample and preserved at −80°C in Trypticase Soy Broth medium (Difco, Sparks, Maryland) with 20% glycerol. 3GCR-EC isolates for each fecal sample were thawed and regrown on MacConkey agar at 37°C for 18 to 24 h for evaluation of antibiotic susceptibility by the disk diffusion method (Kirby Bauer test) on Mueller–Hinton agar (Difco, Sparks, Maryland). To confirm presumptive E. coli isolates, colonies were inoculated onto Chromocult coliform agar (Merck, Darmstadt, Germany).

Antibiotic susceptibility testing

Antibiotic susceptibility testing of all 3GCR-EC isolates was conducted for 10 antibiotics: ampicillin (AM; 10 μg), ceftazidime (CAZ; 30 μg), ciprofloxacin (CIP; 5 μg), cefotaxime (CTX; 30 μg), cefazolin (CZ; 30 μg), cefepime (FEP; 30 μg), gentamicin (GM; 10 μg), imipenem (IPM; 10 μg), trimethoprim/sulfamethoxazole (SXT; 1.25 per 23.75 μg), and tetracycline (TE; 30 μg). Isolates were identified as either susceptible or resistant to each antibiotic according to the resistance or susceptibility interpretation criteria from Clinical and Laboratory Standards Institute (CLSI) guidelines [44]. E. coli ATCC 25922 was used as the quality control strain. Multidrug resistance (resistant to 3 or more classes) was determined based on the number of macro-classes to which each isolate was resistant. Macro-classes were defined as cephalosporin/beta-lactamase inhibitors, penicillins, aminoglycosides, carbapenems, fluoroquinolones, tetracyclines, and folate pathway inhibitors.

For phenotypic confirmation of ESBL production, the combination disk diffusion test was used with CAZ and CAZ/CLA (ceftazidime with clavulanic acid) as outlined in the CLSI guidelines [44]. In the first 4 cycles of data collection, up to 5 E. coli isolates per sample were selected and preserved for analysis. 3GCR-EC isolates from the same fecal sample with identical phenotypic resistance profiles were considered duplicates and were de-duplicated prior to analyses. Due to limited laboratory resources after the SARS-CoV-2 pandemic began in 2020 and the high rate of clonal relationships between E. coli isolated from the same sample (based on preliminary sequencing), only 1 E. coli isolate per sample was selected and preserved for analysis during the fifth cycle of data collection.

DNA sequencing and analysis

Genomic DNA was extracted from the isolates using Wizard Genomic DNA Purification (Promega) kits and QIAGEN DNEasy Blood & Tissue Kits according to the manufacturer’s instructions. We conducted quality control of extracted DNA prior to library creation at the University of Minnesota Genomics Center, including PicoGreen quantification, quantitative capillary electrophoretic sizing (Agilent), and functional quantification (KAPA Biosystems qPCR). Whole-genome sequencing was carried out at the University of Minnesota. In brief, we sequenced whole-genome E. coli isolates using either Illumina MiSeq or NovaSeq with Nextera XT libraries. Following sequencing, raw reads were quality-trimmed and adapter-trimmed using trimmomatic [45]. Assemblies of reads was performed using SPAdes [46], then ARGs were identified using ABRicate (version 0.8.13) and a curated version of the ResFinder database [47]. We also performed in silico multilocus sequence typing (MLST) based on 7 housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, and recA), an additional 8 housekeeping genes (dinB, icdA, pabB, polB, putP, trpA, trpB, and uidA), and core genome (cgMLST) using MLST 2.0 [48] and cgMLSTFinder 1.1 [49]. Detailed methods are previously described [50]. Raw reads from isolates sequenced in this study are available at the NCBI Short Read Archive (SRA) under BioProject accession no. PRJNA861272.

Statistical analyses

Multivariable log-binomial regression models were used to estimate unadjusted and adjusted relative risks (RRs) for the associations between commercial or household food animal exposures and 3GCR-EC and ESBL-EC carriage (i.e., main effects). To control for confounding and strong predictors of the outcomes variables, all adjusted models included prespecified covariates (child age, child sex, child antibiotic use in the past 3 months, household asset score as a proxy for socioeconomic status, and caregiver education level) identified using a directed acyclic graph and existing literature (Fig A in S1 Files) [51]. Next, we included an interaction term in adjusted models, comparing combined effects of household and commercial food animal exposures to a single referent group (unexposed to both commercial and household food animals). We also assessed effect measure modification by estimating the effect of each measure of exposure to commercial food animals among those with versus without food animals (i.e., stratum-specific effects). Estimates and P-values from interaction models were used to determine multiplicative interaction based on an alpha level of <0.10. Finally, we ran additional log-binomial regression models to estimated associations between secondary risk factors of interest related to household animal ownership, animal contact and feces management, and presence of 3GCR-/ESBL-EC in animal stool collected at households. Exposures were treated as binary and categorical using cut-points selected based on the data distribution and interpretability. The outcomes, 3GCR-EC and ESBL-EC carriage, were treated as binary and modelled at the isolate level, adjusting for clustering at the individual/household level and estimating robust standard errors with generalized estimating equations. In a sensitivity analysis, we reproduced this main analysis using only the first E. coli isolate per fecal sample to assess the potential for bias due to the change in number of isolates and probability of detecting the outcomes at each time point. Individual observations with missing exposure, outcome, or covariate data were removed for this complete case analysis. Statistical analyses and visualizations were completed in R version 3.6.1 [38] using the dplyr [52], tableone [53], ggplot2 [54], geepack [55], multcomp [56], and car [57] packages. Exposure and outcome data used in epidemiological analyses are published and publicly available on Dryad (https://doi.org/10.5061/dryad.41ns1rnm7).

Results

A total of 605 households across 7 semirural parishes east of Quito, Ecuador were enrolled throughout the study period between July 2018 and September 2021. We enrolled 374 households in the initial cycle of data collection and recruited new households (using the same enrollment criteria) to enroll in subsequent data collection cycles to account for loss to follow-up. During the fourth cycle, data collection was halted in March 2020 due to lockdown restrictions during the SARS-CoV-2 pandemic, resulting in significant loss to follow-up (39.7%, 151/380 lost to follow-up). However, in the fifth cycle in 2021, we re-enrolled 63.4% (241/380) of participants from cycle 3 and 78.8% (186/236) of participants from cycle 4 (Fig B in S1 Files). A total of 1,739 child fecal samples were collected throughout the study period, from which 920 distinct 3GCR-EC colonies were isolated. Two percent (40/1,739) of child fecal samples were missing corresponding survey data, resulting in a total of 910 3GCR-EC isolates from 1,699 child fecal samples across 600 children from different households. The median number of household visits (i.e., fecal samples) for each child was 3; 23% of the 600 households were visited 5 times, 18% 4 times, 11% 3 times, 11% 2 times, and 37% were visited once. Overall, 1.8% (11/605) of all enrolled households were missing either exposure, outcome, or covariate data and were not included in statistical analyses. After removing children with missing data, 904 3GCR-EC isolates from 1,677 child fecal samples from 594 children remained. This resulted in a total of 1,940 observations (including multiple isolates per fecal sample) in the final dataset for the primary statistical analysis.

Household and child characteristics

In a majority of the 594 included households, most primary caregivers had at least a high school or college level education, ranging from 67.1% to 79.5% across the data collection cycles (Table 1). The average age of children participating in the study was 1.8 years during the first cycle of data collection (Table 2). Access to drinking water and sanitation was high; 98.8% of households had a flush toilet (to sewer or septic tank), 92.2% had piped drinking water inside their home, and 98.6% had 24-h access to drinking water (Table M in S1 Files). Over 93% of households had household handwashing stations with the presence of both soap and water, confirmed by observation (Table 1). However, caregiver-reported child handwashing frequency suggested that most children rarely (44.4% to 69.6%) washed their hands after contact with animals (Table 2). Over the course of the entire study period, 36.7% of caregivers reported that their child played near animal feces in the last 3 weeks, 36.0% reported that their child had contact with livestock at least once per week in the last 3 months, and 67.9% reported child contact with pets at least once per week in the last 3 months. Seven-day caregiver-reported child diarrhea prevalence was 20.3% at the beginning of the study period in 2018 and declined to 4.2% at the final data collection cycle in 2021 during the SARS-CoV-2 pandemic (Table 2). Similarly, treatment for infection in the last 3 months declined from 31.1% at the first cycle to 8.1% at the fifth cycle; child antibiotic use in the last 3 months also declined from 26.2% at cycle 1 to 5.9% at cycle 5 (Table 2).

Table 1. Characteristics of study households in semirural Quito, Ecuador at each cycle of data collection between July 2018 and September 2021.

Data collection cycle
1
n (%)
2
n (%)
3
n (%)
4
n (%)
5
n (%)
Total 370 (100) 358 (100) 365 (100) 225 (100) 356 (100)
Parish
 El Quinche 20 (5.4) 17 (4.7) 30 (8.2) 16 (7.1) 26 (7.3)
 Puembo 20 (5.4) 21 (5.9) 37 (10.1) 16 (7.1) 23 (6.5)
 Pifo 86 (23.2) 77 (21.5) 75 (20.5) 55 (24.4) 75 (21.1)
 Tababela 12 (3.2) 9 (2.5) 8 (2.2) 6 (2.7) 13 (3.7)
 Tumbaco 23 (6.2) 35 (9.8) 24 (6.6) 17 (7.6) 22 (6.2)
 Yaruqui 146 (39.5) 146 (40.8) 141 (38.6) 80 (35.6) 141 (39.6)
 Missing 4 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Caregiver education level
 High school or college 276 (74.6) 263 (73.5) 256 (70.1) 151 (67.1) 283 (79.5)
 Elementary 93 (25.1) 95 (26.5) 108 (29.6) 68 (30.2) 69 (19.4)
 Missing 1 (0.3) 0 (0.0) 1 (0.3) 6 (2.7) 4 (1.1)
Household size (mean (SD)) 4.5 (1.4) 4.6 (1.5) 4.6 (1.4) 4.4 (1.2) 4.4 (1.5)
Household water treatment
 No treatment 194 (52.4) 170 (47.5) 223 (61.1) 138 (61.3) 229 (64.3)
 Boil 159 (43.0) 154 (43.0) 119 (32.6) 68 (30.2) 109 (30.6)
 Chlorinate or filter 3 (0.8) 5 (1.4) 5 (1.3) 3 (1.3) 2 (0.6)
 Other 14 (3.8) 29 (8.1) 18 (4.9) 16 (7.1) 16 (4.5)
Household handwashing station
 Soap and water 354 (95.7) 344 (96.1) 347 (95.1) 211 (93.8) 340 (95.5)
 Soap or water, only 9 (2.4) 14 (4.0) 17 (4.7) 14 (6.2) 16 (4.5)
 Neither 6 (1.6) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
 Missing 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Caregiver worked with animals in past 6 months a 105 (28.4) 79 (22.1) 80 (21.9) 73 (32.4) 113 (31.7)
Household owns animals 233 (63.0) 241 (67.3) 244 (66.8) 157 (69.8) 236 (66.3)
 Missing 3 (0.8) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Household owns food animals 110 (29.7) 117 (32.7) 107 (29.3) 63 (28.0) 92 (25.8)
 Missing 2 (0.5) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Household food animals (mean (SD)) 6.9 (19.3) 5.7 (14.1) 6.9 (19.1) 9.2 (39.4) 5.9 (21.3)
Antibiotic use for household food animals 29 (26.4) 22 (18.8) 11 (10.3) 6 (9.5) 0 (0.0)
 Missing 7 (6.4) 4 (3.4) 1 (0.9) 0 (0.0) 9 (9.8)
Distance to nearest commercial food animal operation
 ≥1.5 km 155 (41.9) 162 (45.3) 154 (42.2) 97 (43.1) 170 (47.8)
 1–1.49 km 90 (24.3) 86 (24.0) 87 (23.8) 52 (23.1) 70 (19.7)
 0.5–0.9 km 60 (16.2) 54 (15.1) 73 (20.0) 45 (20.0) 71 (19.9)
 <0.5 km 61 (16.5) 56 (15.6) 51 (14.0) 31 (13.8) 45 (12.6)
 Missing 4 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Commercial food animal operations within 5 km radius
 ≤5 115 (31.1) 118 (33.0) 113 (31.0) 71 (31.6) 203 (57.0)
 6–10 93 (25.1) 89 (24.9) 84 (23.0) 52 (23.1) 44 (12.4)
 11–20 88 (23.8) 90 (25.1) 76 (20.8) 51 (22.7) 47 (13.2)
 >20 70 (18.9) 61 (17.0) 92 (25.2) 51 (22.7) 62 (17.4)
 Missing 4 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Distance to drainage path of commercial food animal operation
 >500 m 154 (41.6) 161 (45.0) 150 (41.1) 99 (44.0) 167 (46.9)
 101–500 m 158 (42.7) 133 (37.2) 162 (44.4) 92 (40.9) 138 (38.8)
 ≤100 m 60 (16.2) 67 (18.7) 59 (16.2) 39 (17.3) 56 (15.7)
 Missing 4 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)

a Including working with live animals, with animal feces, or in meat processing.

Table 2. Characteristics and behaviors of children in study households at each cycle of data collection between July 2018 and September 2021.

Data collection cycle
1
n (%)
2
n (%)
3
n (%)
4
n (%)
5
n (%)
Total 370 (100) 358 (100) 365 (100) 225 (100) 356 (100)
Child age in years (mean (SD)) 1.8 (1.3) 2.0 (1.3) 2.4 (1.4) 3.0 (1.3) 3.8 (1.6)
Child sex
 Female 171 (46.2) 162 (45.3) 154 (42.2) 96 (42.7) 158 (44.4)
 Male 199 (53.8) 196 (54.7) 211 (57.8) 129 (57.3) 198 (55.6)
Child contact with livestock in last 3 months
 Never 248 (67.0) 254 (70.9) 238 (65.2) 126 (56.0) 205 (57.6)
 <1 time per week 42 (11.4) 26 (7.3) 54 (14.8) 14 (6.2) 25 (7.0)
 1–2 times per week 31 (8.4) 32 (8.9) 39 (10.7) 50 (22.2) 50 (14.0)
 3+ times per week 49 (13.2) 46 (12.8) 34 (9.3) 35 (15.6) 75 (21.1)
 Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Child contact with pets in last 3 months
 Never 132 (35.7) 122 (34.1) 108 (29.6) 64 (28.4) 112 (31.5)
 <1 time per week 54 (14.6) 34 (9.5) 65 (17.8) 12 (5.3) 23 (6.5)
 1–2 times per week 52 (14.1) 50 (14.0) 73 (20.0) 59 (26.2) 50 (14.0)
 3+ times per week 132 (35.7) 152 (42.5) 119 (32.6) 90 (40.0) 171 (48.0)
Child played near animal feces in last 3 weeks 115 (31.1) 99 (27.7) 148 (40.5) 77 (34.2) 175 (49.2)
 Missing 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.8)
Child handwashing after contact with animals
 Never 43 (11.6) 13 (3.6) 4 (1.1) 3 (1.3) 3 (0.8)
 Rarely 185 (50.0) 249 (69.6) 245 (67.1) 129 (57.3) 158 (44.4)
 Sometimes 83 (22.4) 68 (19.0) 109 (29.9) 87 (38.7) 159 (44.7)
 Always 18 (4.9) 9 (2.5) 7 (1.9) 6 (2.7) 36 (10.1)
 Do not know/does not apply 41 (11.1) 19 (5.3) 0 (0.0) 0 (0.0) 0 (0.0)
Child had diarrhea in last 7 days 75 (20.3) 77 (21.5) 43 (11.8) 36 (16.0) 15 (4.2)
 Missing 2 (0.5) 1 (0.3) 1 (0.3) 0 (0.0) 2 (0.6)
Child treated for infection in last 3 months 115 (31.1) 98 (27.4) 84 (23.0) 54 (24.0) 29 (8.1)
 Missing 3 (0.8) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Child took antibiotics in last 3 months 97 (26.2) 67 (18.7) 63 (17.3) 26 (11.6) 21 (5.9)
 Missing 0 (0.0) 2 (0.6) 0 (0.0) 0 (0.0) 0 (0.0)

Food animal production and domestic animals

We identified 130 active commercial food animal operations in our study site including 122 poultry facilities, 5 hog facilities, 2 horse facilities, and 1 milk production facility. Across the 7 parishes in the study site, 4 parishes (Tababela, Tumbaco, Checa (Chilpa), and Pifo) had low-intensity commercial production with fewer than 10 commercial food animal operations, each. Three parishes (El Quinche, Puembo, and Yaruqui) had high-intensity production, with more than 30 commercial food animal operations, each (Table F in S1 Files). More than half of study households were located <1.5 km from a commercial food animal operation (55.7%) or were within 500 m of a commercial operation’s drainage flow path (56.1%) throughout the study period. During the first 4 cycles of data collection, at least 67% of households were within 5 km of 6 or more commercial food animal operations; this dropped to 43% in the fifth cycle (Table 1).

We collected 1,871 animal fecal samples from 376 matched households and identified 1,060 3GCR-EC isolates to assess as a potential risk factor. Throughout the study period, 66.4% of caregivers reported owning any type of animal, with 29.2% owning food animals and an average of 5.7 to 9.2 food animals at each data collection cycle (Table 1). Among households that owned food animals, reported antibiotic use in food animals was low, declining from 26.4% at the beginning of the study period to 0% at the end of the study (Table 1). Thirty-two percent of households owned backyard chickens, 17% owned guinea pigs, 11% owned pigs, 7% owned cattle, and 3% owned goats or sheep. The average flock size for backyard chickens was 13.7 (standard deviation (SD): 29.9). There was an average of 16 guinea pigs (SD: 19.6), 4.3 pigs (SD: 6.6), 2.8 cows (SD: 2.6), 2.9 goats (SD: 3.2), and 4.0 sheep (SD: 6.3). Eighty percent of households owned dogs, with an average of 2.3 dogs per household (SD: 1.6).

Characterization of 3GCR-EC isolates

Sixty-one percent of children (n = 365/600) were carriers of 3GCR-EC and 25% (n = 149/600) were carriers of ESBL-EC at least once throughout the study period. 3GCR-EC were detected in 38% of child samples (n = 652/1,699) and 51% of animal samples (n = 959/1,871) from matched households. Of 910 3GCR-EC isolated from child samples, 36% were resistant to fourth-generation cephalosporin, cefepime, in phenotypic susceptibility testing (Table B in S1 Files). Eighty-six percent of child 3GCR-EC isolates were multidrug-resistant (3 or more classes), 37% were extensively drug-resistant (5 or more classes), and 22% were phenotypic ESBL producers (Table B in S1 Files). Notably, 5 children (<1%) from different households had 1 E. coli isolate that was phenotypically resistant to the carbapenem drug, imipenem (Table B in S1 Files). All of these imipenem-resistant isolates were multidrug-resistant to 4 or more drug classes, with each isolate also expressing resistance to ampicillin and cephalosporin antibiotics. Phenotypic resistance to antibiotics among 3GCR-EC isolates from animal fecal samples are described in Table C in S1 Files.

We analyzed whole-genome sequencing data for a subset of 571 3GCR-EC isolated from fecal samples of the 365 children that were 3GCR-EC carriers. We first selected 1 isolate per child for sequencing, then aimed to randomly select an additional 200 isolates to include more ESBL-EC in sequencing analyses. The most prevalent sequence type (ST) among these isolates was ST 10 (7%, 40/571), while other clinically important STs like ST 131 and ST 117 accounted for about 3% of sequenced isolates (Table D in S1 Files). 3GCR-EC isolates had a mean of 9.7 total ARGs (SD: 4.3). Overall, the proportion of 3GCR-EC isolates with bla genes was 65%, 52%, 8%, 5%, and 5% for blaCTX-M-encoding, blaTEM, blaCMY, blaOXA, and blaSHV genes, respectively. Ten (2%) 3GCR-EC isolates had an mcr-1 gene, indicating resistance to the last-line antibiotic colistin. Eighty-two percent (n = 119/145) of phenotypic ESBL-EC and 77% (n = 330/426) of non-ESBL-producing 3GCR-EC carried at least 1 bla gene. Among phenotypic ESBL-EC, the most prevalent bla genes were blaCTX-M-55, blaTEM-141, blaTEM-1B, blaCTX-M-15, and blaOXA-1 (Table E in S1 Files). Among the most prevalent CTX-M-encoding genes, the most prevalent genes in parishes with high-intensity commercial food animal production were blaCTX-M-55, blaCTX-M-65, blaCTX-M-15, and blaCTX-M-14 (Fig 2 and Table H in S1 Files). Parishes with lower intensity commercial food animal production had a higher prevalence of blaCTX-M-3, though blaCTX-M-55, blaCTX-M-65, and blaCTX-M-15 were also detected in these parishes (Fig 2 and Table H in S1 Files).

Fig 2. Map of distribution of CTX-M-type genes from a subset of 571 3GCR-EC isolated from children in 7 parishes east of Quito, Ecuador.

Fig 2

Pie chart sections represent the proportion of isolates with a specific CTX-M-type gene detected, among those represented in the plot legend. Shaded areas represent parishes, where darker shading indicates a higher number of commercial food animal operations in a given parish. Map created in RStudio; Ecuador parish boundary shapefiles are made publicly available by the INEC and the United Nations OCHA. Data and license information are available at https://data.humdata.org/dataset/cod-ab-ecu?. 3GCR-EC, third-generation cephalosporin-resistant E. coli; INEC, Instituto Nacional de Estadística y Censos; OCHA, Office for the Coordination of Humanitarian Affairs.

Risk factors for 3GCR-EC

The prevalence of 3GCR-EC was higher in all food animal exposure groups compared to the unexposed, where the denominators include all fecal samples and isolates within each exposure group (Fig 3). In models assessing main effects of household and commercial food animal exposures, the density of commercial operations (>5 in 5 km radius) was the only exposure associated with an increased risk of 3GCR-EC (RR: 1.27; 95% CI: 1.11, 1.46) (Table 3). In models adjusting for interaction between household and commercial food animal exposures, children with >5 commercial food animal operations in a 5-km radius of their household had 1.36 times the risk (95% confidence interval (CI): 1.16, 1.59) of 3GCR-EC carriage than those with ≤5 operations within 5 km when controlling for household food animal ownership (Table 4). However, among those with household food animals, there was no effect of commercial operation density on 3GCR-EC carriage (RR: 1.05; 95% CI: 0.83, 1.33) (Table 4). There was not an excess risk of being exposed to both household food animals and >5 commercial operations (relative excess risk due to interaction (RERI): −0.29, 95% CI: −0.64, 0.06) (Table 4). However, the combination of owning household food animals and living <1.5 km from the nearest commercial operation was associated—with borderline significance—with an increased risk in 3GCR-EC carriage (RR: 1.15; 95% CI: 0.98, 1.36) compared to those without food animals who lived further from commercial food animal operations (Table 4). Proximity to a drainage flow path from a commercial food animal operation was not associated with 3GCR-EC carriage, regardless of household food animal ownership (Table 4). These results were largely robust to sensitivity analyses (Table I in S1 Files). Other risk factors for 3GCR-EC among children included child pet contact in the last 3 months (RR: 1.23; 95% CI: 1.09, 1.39) and pig ownership (RR: 1.23; 95% CI: 1.02, 1.48) (Fig 4) (Table J in S1 Files).

Fig 3. Bar plot of distribution of 3GCR-EC and ESBL-EC carriage stratified by exposures to HH food animals and CFOs.

Fig 3

Number of observations includes fecal samples that were negative for 3GCR-EC (light gray bars for 3GCR-EC), isolates from fecal samples that were 3GCR-EC (orange bars), or ESBL-EC (purple bars) based on phenotypic susceptibility testing, and isolates plus fecal samples negative for both 3GCR-EC and ESBL-EC (light gray bars for ESBL-EC). Percent of observations positive for each outcome are listed above each bar. 3GCR-EC, third-generation cephalosporin-resistant E. coli; CFO, commercial food animal operation; ESBL-EC, extended-spectrum beta-lactamase E. coli; HH, household.

Table 3. Unadjusted and adjusted RRs of 3GCR-EC and ESBL-EC for main effects of household food animal ownership and exposures to commercial food animal production.

3GCR-EC ESBL-EC
Unadjusted RR (95% CI) P-Value Adjusted RR (95% CI) P-Value Unadjusted RR (95% CI) P-Value Adjusted RR (95% CI) P-Value
Household owns food animals (ref = no)a 1.06 (0.94, 1.19) 0.388 1.04 (0.92, 1.17) 0.521 1.12 (0.82, 1.52) 0.472 1.10 (0.81, 1.51) 0.541
> 5 CFO in 5 km radius (ref = ≤5)b 1.26 (1.10, 1.45) 0.001 1.27 (1.11, 1.46) 0.001 1.12 (0.84, 1.51) 0.444 1.14 (0.84, 1.53) 0.404
< 1.5 km to nearest CFO (ref = ≥ 1.5 km)b 1.21 (0.84, 1.75) 0.305 1.10 (0.98, 1.25) 0.118 1.24 (0.60, 2.60) 0.561 0.91 (0.68, 1.22) 0.520
101–500 m to CFO drainage path (ref = >500 m)b 1.05 (0.91, 1.21) 0.486 1.04 (0.91, 1.20) 0.563 1.14 (0.83, 1.57) 0.426 1.15 (0.83, 1.59) 0.392
0–100 m to CFO drainage path (ref = >500 m)b 1.13 (0.96, 1.33) 0.132 1.08 (0.92, 1.27) 0.331 1.15 (0.77, 1.71) 0.510 1.15 (0.77, 1.72) 0.499

All RRs estimated with log-binomial regression models using generalized estimating equations to adjust for repeated measures and estimate robust 95% CI. Adjusted RR included the following covariates: caregiver education, asset score, child age and sex, and child antibiotic use in the last 3 months. N = 1,940 observations across 1,677 child fecal samples (including 910 total 3GCR-EC isolates) for 594 children. CFO = commercial food animal operation. RR: relative risk. CI: confidence interval. 3GCR-EC: third-generation cephalosporin-resistant E. coli. ESBL-EC: extended-spectrum beta-lactamase producing E. coli.

a Adjusted models also controlled for number of commercial food animal productions in 5km radius.

b Adjusted models also controlled for household food animal ownership.

Table 4. Adjusted RRs of 3GCR-EC carriage among children given combined exposures to commercial food animal production and effect measure modification by household food animal ownership.

Adjusted RR for 3GCR-EC (95% CI) Interaction P-value RERI (95% CI)
No household food animals Household food animals
No. CFOs in 5 km radius ≤5 1.00 (ref) 1.22 (0.95, 1.55) - -
>5 1.36 (1.16, 1.59) 1.28 (1.06, 1.54) 0.077 −0.29 (−0.64, 0.06)
>5 within strata of household food animals 1.36 (1.16, 1.59) 1.05 (0.83, 1.33) - -
Distance to nearest CFO ≥1.5 km 1.00 (ref) 1.02 (0.83, 1.26) - -
<1.5 km 1.09 (0.95, 1.27) 1.15 (0.98, 1.36) 0.827 0.03 (−0.23, 0.30)
<1.5 km within strata of household food animals 1.09 (0.95, 1.27) 1.13 (0.91, 1.39) - -
Distance to nearest CFO drainage path >500 m 1.00 (ref) 0.98 (0.80, 1.21) - -
101–500 m 1.00 (0.85, 1.18) 1.16 (0.90, 1.49) 0.327 0.16 (−0.14, 0.45)
≤100 m 1.10 (0.91, 1.34) 1.07 (0.82, 1.38) 0.818 −0.04 (−0.36, 0.28)
101–500 m within strata of household food animals 1.00 (0.85, 1.18) 1.14 (0.93, 1.39) - -
≤100 m within strata of household food animals 1.10 (0.91, 1.34) 1.05 (0.84, 1.31) - -

Log-binomial regression models with generalized estimating equations included interaction terms between commercial and household food animal exposure variables, and included the following covariates: caregiver education, asset score, child age and sex, and child antibiotic use in the last 3 months. N = 1,940 observations across 1,677 child fecal samples (including 910 total 3GCR-EC isolates) for 594 children. CFO = commercial food animal operation. RR: relative risk. CI: confidence interval. 3GCR-EC: third-generation cephalosporin-resistant E. coli. RERI: relative excess risk due to interaction.

Fig 4. Additional risk factors for 3GCR-EC and ESBL-EC carriage among children in semirural parishes of Quito, Ecuador.

Fig 4

Points are adjusted RR and error bars are 95% CIs; asterisks (*) indicate significance given alpha = 0.05 (corresponding data including sample sizes and P-values in Tables K and J in S1 Files). RR are adjusted for repeated measures and controlled for the following covariates: caregiver education, asset score, child age and sex, and child antibiotic use in the last 3 months. 3GCR-EC, third-generation cephalosporin-resistant E. coli; CI, confidence interval; ESBL-EC, extended-spectrum beta-lactamase E. coli; RR, relative risk.

Risk factors for ESBL-EC

We did not detect significant associations or interactions between the density of or proximity to commercial food animal operations, household food animal ownership, and ESBL-EC carriage. In models adjusting for interactions between exposures, household food animal ownership and increased proximity to a drainage path were not significantly associated with an increased risk of ESBL-EC carriage among children. However, the effect sizes were larger for combined and increasing intensity of exposures. When controlling for household food animal ownership, the RR for ESBL-EC was 1.10 (95% CI: 0.76, 1.60) for those living 101 to 500 m from a drainage path and was 1.32 (95% CI: 0.71, 2.46) for those 101 to 500 m from a drainage path compared to those >500 m (Table 5). The RR further increased to 1.80 (95% CI: 0.94, 3.45) for those living within 100 m of a drainage path and with household food animals compared to those >500 m from a drainage path and without household food animals; this interaction was near-significant with an interaction P-value of 0.108 (RERI: 0.85; 95% CI: −0.10, 1.81) (Table 5). These findings were also robust to sensitivity analyses (Table I in S1 Files). Additional risk factors of ESBL-EC carriage among children in our study site included placing animal feces on household land/crops (RR: 1.63; 95% CI: 1.09, 2.46), household dog ownership (RR: 1.35; 95% CI: 1.00, 1.83), and child pet contact in the last 3 months (RR: 1.54; 95% CI: 1.10, 2.16) (Fig 4 and Table K in S1 Files).

Table 5. Adjusted RRs of ESBL-EC carriage among children given combined exposures to commercial food animal production and household food animals, including both interaction effects (effects of individual and combined exposures vs. no exposures) and stratum-specific effects (effects of commercial food animal exposures within strata of household food animal ownership vs. no exposures).

Adjusted RR for ESBL-EC (95% CI) Interaction P-value RERI (95% CI)
No household food animals Household food animals
No. CFOs in 5 km radius ≤5 1.00 (ref) 1.18 (0.69, 2.01) - -
>5 1.17 (0.82, 1.68) 1.24 (0.82, 1.86) 0.737 −0.12 (−0.89, 0.66)
>5 within strata of household food animals 1.17 (0.82, 1.68) 1.05 (0.61, 1.81) - -
Distance to nearest CFO ≥1.5 km 1.00 (ref) 0.91 (0.57, 1.46) - -
<1.5 km 0.81 (0.57, 1.16) 1.05 (0.69, 1.59) 0.268 0.32 (−0.23, 0.88)
<1.5 km within strata of household food animals 0.81 (0.57, 1.16) 1.15 (0.70, 1.91) - -
Distance to nearest CFO drainage path >500 m 1.00 (ref) 0.88 (0.50, 1.53) - -
101–500 m 1.10 (0.76, 1.60) 1.32 (0.71, 2.46) 0.619 0.18 (−0.53, 0.89)
≤100 m 0.85 (0.46, 1.57) 1.80 (0.94, 3.45) 0.108 0.85 (−0.10, 1.81)
101–500 m within strata of household food animals 1.10 (0.76, 1.60) 1.15 (0.73, 1.83) - -
≤100 m within strata of household food animals 0.85 (0.46, 1.57) 1.24 (0.82, 1.86) - -

RRs and robust 95% CIs estimated using log-binomial regression models with generalized estimating equations included interaction terms between commercial and household food animal exposure variables and included the following covariates: caregiver education, asset score, child age and sex, and child antibiotic use in the last 3 months. N = 1,940 observations across 1,677 child fecal samples (including 910 total 3GCR-EC isolates) for 594 children. CFO = commercial food animal operation. RR: relative risk. CI: confidence interval. 3GCR-EC: third-generation cephalosporin-resistant E. coli. RERI: relative excess risk due to interaction.

Discussion

In this study of 7 semirural parishes in Ecuador, we found that increased density of commercial food animal production facilities, household food animal ownership, child pet contact, and rarely/never washing hands after contact with animals were risk factors for 3GCR-EC carriage. The combination of owning household food animals and living within 100 m of a drainage flow path from a commercial food animal operation may have increased the risk of ESBL-EC carriage among children. Other risk factors for ESBL-EC carriage were household dog ownership, child pet contact, and placing animal feces on household land/crops. Clinically relevant STs such as ST 10, ST 131, ST 38, and ST 117 associated with extraintestinal pathogenic E. coli (ExPEC) were detected in child fecal samples, highlighting the public health significance of community-acquired ESBL-producing E. coli carriage [58]. The results of this study emphasize the need for a One Health approach in the control and prevention of antibiotic-resistant bacterial (ARB) infections, particularly in the context of globally expanding commercial food animal production.

Epidemiologic studies have established a clear link between commercial food animal production and ARB carriage among commercial animal farm workers, their household contacts, and community members [19,5963]. Epidemiological research on associations between small-scale food animal production and community-acquired resistance in humans, however, has been limited. Previous studies have used samples that are not spatiotemporally matched with household-level exposures, cross-sectional study designs, small sample sizes, or descriptive statistics, only [6467]. These methodological limitations prevent the reliable estimation of associations between small-scale food animal exposures and community-acquired antibiotic-resistant infections. This study attempted to address these gaps by leveraging repeated measures data from 600 households in which household-level exposure data—including data on ARB carriage in household animals—are spatiotemporally matched with outcome data. With our robust longitudinal One Health study design, we were able to estimate the impacts of food animal exposures, domestic animal exposures, and hygiene practices on antibiotic-resistant E. coli carriage in children.

Prevalence estimates in the literature suggest that community-acquired ESBL-EC carriage in healthy populations is increasing globally, with a recent pooled estimate of 21% in 2015 to 2018 [16]. However, there are few studies estimating community-acquired ESBL-producing infections in South America, and estimates are variable. Bezabih and colleagues (2021) estimated a pooled ESBL-EC prevalence of <10% for the Americas, while a 2015 review of ESBL-E estimated a prevalence of 2% for the Americas [68]; both reviews included estimates from studies from the United States in pooled estimates and did not include any studies from Ecuador. Of note, studies in these reviews used selective media to screen for 3GCR-EC or ESBL-EC prior to ESBL confirmatory testing, comparable to the methods used in the present study. A 2008 multicountry study in South and Central America (not including Ecuador) detected ESBL-producing bacteria in 31% of community-acquired intra-abdominal infections [69]. The high prevalence of 3GCR-EC, ESBL-EC, and MDR E. coli carriage among healthy children in our study site is concerning. Over 60% of children were carriers of 3GCR-EC with frequent detection of blaCTX-M genes and 25% were carriers of ESBL-EC at least once throughout the study period, with 86% of all 3GCR-EC being MDR. Even among non-ESBL-producing E. coli isolates based on phenotypic testing, bla genes encoding for extended-spectrum beta-lactam resistance were detected in over 75% of 3GCR-EC isolates. CTX-M-encoding genes blaCTX-M-55, blaCTX-M-65, and blaCTX-M-15 were the most frequently detected bla genes in this food animal-producing region of Ecuador. blaCTX-M-55, blaCTX-M-65, and blaCTX-M-15 are dominant in food animals such as chickens, pigs, and cattle, as well as meat products in China, South Korea, Hong Kong, Canada, Portugal, and elsewhere [7074]. The distribution of CTX-M-encoding genes in our study site suggests that food animal production plays a critical role in driving the community spread of 3GCR-EC and ESBL-EC in this region of Ecuador.

Other analyses of data collected for this cohort study have previously provided evidence for both horizontal gene transfer and clonal spread of 3GCR-EC in children and animals within and between households in the study site [50,75]. Animal waste management and handling practices were poor in a majority of households with clonal relationships between 3GCR-EC in children and animals [50]. Though evidence of resistant bacteria transmission between backyard chickens, dogs, and humans has been documented in this study site and study period through previous analyses [50,75], it is unclear whether antibiotic use in household food animals and domestic animals or human antibiotic use is driving selection of resistant bacteria in these communities. In fact, reported antibiotic use in children and household animals was low in this study site and participants had limited knowledge about antibiotics and antibiotic stewardship [34]. A recent qualitative study in the same communities found that small-scale poultry and livestock producers typically rely on low-cost traditional veterinary practices rather than administering antibiotics [76]. Notably, antibiotic use in children and domestic animals declined throughout the study period. One possible explanation is that public health measures such as the SARS-CoV-2 pandemic lockdowns may have curbed infectious disease transmission in humans, reducing the need for antibiotic treatment [77]. This hypothesis is supported by the apparent reduction in reported child illness from cycle 3 (before pandemic lockdowns) to cycle 5 (after lockdowns began) in our study. These observed secular trends appear to be nondifferential by household food animal ownership (Table L in S1 Files).

While antibiotic use in household food animals may not be a primary driver of resistance in this area, commercial-scale production operations administering high volumes of antibiotics may be a key driver of emergence and selection of resistant bacteria [1,19]. Results from our study suggest that household food animals and domestic animals still play an important role in determining risk of antibiotic-resistant E. coli carriage among community members. Household animals may act as a vector for transmission of resistant bacteria between environmental reservoirs contaminated by commercial food animal waste and humans with whom they come into contact. GPS-tracked movement patterns of free-range poultry in northwestern Ecuador confirmed that backyard chickens (not given antibiotics) travel an average of 17 m from their household and that this range overlapped with small-scale farms of broiler chickens (given antibiotics) [78]. Free-roaming dogs are also common in urban and rural Quito [79] and have been shown to roam up to 28 km from their homes on average in rural Southern Chile [80]. While some backyard chickens in our study site were kept in coops, some free-range chickens and free-roaming dogs may have been exposed to ARB in environmental contamination from nearby commercial operations. For example, animals may be exposed to high levels of fecal contamination in irrigation canals [81], though household animals drinking irrigation water was not identified as a significant risk factor for human ARB carriage in our study. Household members may be exposed to ARB through contact with companion animals, food animals, or their feces. In fact, children with recent contact with pets, from households with ESBL+ animal feces in the yard, or from households that applied animal waste to household food crops had a slightly greater risk of ESBL-EC colonization in our study. We also reported increasing RRs of ESBL-EC for children in households that both owned food animals and were close to a commercial food animal operation drainage path, which often feed into irrigation canals. Furthermore, the irrigation canals run throughout the study site, which may, in part, drive the geographic spread of beta-lactamase genes we detected in parishes with both high and low numbers of commercial production facilities.

A limitation of the present study is the change in the number of E. coli isolated per sample midway through the study. This may impact the probability of detecting the outcome; for example, phenotypic ESBL-EC would be more likely to be detected for a child with multiple isolates tested for ESBL production compared to a child with only 1 isolate tested. We attempted to address this by analyzing data at the isolate level and adjusting for imbalanced data in our statistical approach rather than aggregating the binary outcome at the individual level. We also included a sensitivity analysis using only the first isolate per sample. Despite some slight differences in point estimates, the overall findings were robust to sensitivity analyses, suggesting a low risk of bias in our outcome assessment methods. Another limitation is that we only isolated 3GCR-EC in order to improve detection of ESBL-EC, limiting our findings to this specific type of ARB species. We did not identify other ESBL-producing Enterobacterales, such as Klebsiella pneumoniae, which also have clinical importance given the high mortality rates associated with ESBL-producing K. pneumoniae infections [82]. Finally, the CLSI guidelines indicate the use of CAZ and CAZ/CLA as well as CTX and CTX/CLA for confirmatory ESBL testing; if a ≥5-mm difference in at least one of these combinations is identified, it is correct to consider the isolate tested as an ESBL-producing isolate. For this study, we evaluated ESBL-production based on the CAZ and CAZ/CLA combination disk diffusion test alone. Therefore, some ESBL-negative isolates reported in the manuscript had the potential to be ESBL-positive if we also had evaluated CTX and CTX/CLA. Based on CLSI guidelines and methods used in this study, all of the ESBL-positive isolates detected and reported in our manuscript are ESBL-positive. The difference between the number of isolates with ESBL genes and isolates with ESBL expression (phenotypically resistant) may be due to the methodology used (only using CAZ and CAZ/CLA and not CTX and CTX/CLA).

Additionally, several risk factors were based on caregiver-reported information and are subject to recall bias. We attempted to reduce bias by asking caregivers to recall weekly frequencies of events (e.g., child contact with animals) over longer periods of time (e.g., 3 months), rather than asking for “yes/no” responses. Finally, this study was halted in the middle of the fourth cycle of data collection due to SARS-CoV-2 lockdowns in March 2020 and did not resume until April 2021, resulting in significant participant dropout. Prior to the pandemic, there was some dropout to do migration out of the study site. This loss to follow-up may have induced some selection bias, though we aimed to address the imbalanced nature of the data in our statistical approach using semiparametric generalized estimating equations with an exchangeable working correlation.

A significant challenge in identifying the source of ARB remains: There is a lack of available data on antibiotic usage and resistance in intensive, commercial food animal operations and their effluent in Ecuador and globally due to limited oversight and surveillance. To accurately characterize the extent to which antibiotic use in commercial production drives community-acquired antibiotic-resistant infections, policies should require that commercial food animal operations monitor and report antibiotic use and conduct routine surveillance for antibiotic-resistant bacteria in food animals, food animal production waste, nearby environmental reservoirs, and food animal products. Future studies should attempt to collect this data to characterize ARB in commercial food animal production settings in Quito. Local and national policies requiring improved waste management practices in large-scale commercial food animal production operations are also lacking, especially in LMICs [83]. Strategies may include containing and/or diverting animal waste, moving animal grazing areas away from waterways, transporting excess waste to more remote areas with sufficient non-food crop land to apply waste as fertilizer, and monitoring levels of nutrients and antibiotic-resistant bacteria in soil and waterways near discharge points. Governments could implement a permitting process that requires commercial operations to submit a waste management plan for approval by agriculture and environmental protection agencies. For example, in the United States, the Environmental Protection Agency established the National Pollution Discharge Elimination System, which regulates the discharge of pollution from point sources at large animal feeding operations and other industrial sites to bodies of water. Agencies could provide subsidies to support producers with initial costs of improving waste management. Policies and regulations should be tailored to farm size; some practices may be cost-prohibitive for small-scale producers, so appropriate financial incentives should be used to promote best management practices among small food animal farms [84]. Finally, national policies should follow global recommendations to restrict the use of clinically important antibiotics like third-generation cephalosporins in food animals [85]. Restricting antibiotic use in cattle farms has been shown to reduce detection of blaCTX-M genes in cattle [86]. To improve the effectiveness of such policies, antibiotic stewardship training programs from a One Health lens could be offered to physicians, veterinarians, and food animal producers with an emphasis on the growing antibiotic resistance crisis.

Our study underscores the need for increased monitoring of waste management practices and improved surveillance of antibiotic use and community-acquired antibiotic resistance in LMICs with widespread food animal production. Increased contact with domestic animals, household food animal ownership, and proximity to large-scale food animal production operations—especially in high-density areas—were associated with an increased risk of antibiotic-resistant bacteria carriage in young children. With zoonotic infectious disease risks and hygiene-related prevention strategies at the forefront of public health messaging due to the SARS-CoV-2 pandemic, national governments should prioritize policies and communication strategies that promote improved food animal waste management and safe hygiene practices to reduce the prevalence of ARB carriage and infections.

Supporting information

S1 Files. Supplementary files.

Checklist: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist of items that should be included in reports of cohort studies. Sample Size and Power Calculations. Table A. Prevalence of third-generation cephalosporin-resistant, extended-spectrum beta-lactamase, multidrug-resistant, and extensively drug-resistant E. coli among children. Table B. Proportion of third-generation cephalosporin-resistant E. coli (3GCR-EC) isolates resistant to individual antibiotics in phenotypic susceptibility testing by data collection cycle. Table C. Antibiotic resistance of 3GCR-EC isolates from animal fecal samples (1 colony isolated per fecal sample) collected at the same households as child fecal samples, stratified by animal species. Table D. Prevalence of clinically important sequence types (ST) among sequenced 3GCR-EC isolates (N = 571) from child fecal samples. Table E. Proportion of 3GCR-EC isolates with beta-lactamase genes (among 15 most prevalent) detected in whole-genome sequences, stratified by phenotypic ESBL production. Table F. Prevalence of beta-lactamase resistance genes among sequenced 3GCR-EC isolates from children, stratified by parishes and intensity of commercial food animal production. Table G. Average number of total antibiotic resistance genes (ARGs) per third-generation cephalosporin-resistant E. coli isolate from children, stratified by parish. Table H. Prevalence of CTX-M-type genes among sequenced 3GCR-EC isolates from children, stratified by parish and intensity of commercial food animal production. Table I. Sensitivity analysis results for main analysis associations between combined food animal exposures and 3GCR-EC and ESBL-EC including only 1 isolate per child fecal sample. Table J. Associations between secondary risk factors and 3GCR-EC carriage among children. Table K. Associations between secondary risk factors and ESBL-EC carriage among children. Table L. Secular trends in caregiver-reported child illness and antibiotic use stratified by household food animal ownership. Table M. Access to water and sanitation at households included in the main analysis (N = 594). Fig A. Directed acyclic graph of causal relationship between exposures to commercial and household food animal production and ESBL-E. coli carriage in children. SES: socioeconomic status. ESBL: extended-spectrum beta-lactamase E. coli. Fig B. Flow chart of enrollment and follow-up by data collection cycle. Households were included in the final analysis if they had the necessary exposure, outcome, and covariate data. Fig C. Prevalence of beta-lactamase genes (top 15 most prevalent) among sequenced third-generation cephalosporin-resistant E. coli isolates from children, stratified by phenotypic extended-spectrum beta-lactamase (ESBL) production. Fig D. Prevalence of beta-lactamase genes by type among third-generation cephalosporin-resistant E. coli (3GCR-EC) isolated from children, stratified by parish.

(DOCX)

Acknowledgments

We sincerely thank the data collection team and community partners in Ecuador for their hard work, time, and dedication to this research, especially through the SARS-CoV-2 pandemic. Thanks to Kathleen Kurowski and Rachel Marusinec for their contributions to laboratory work during the initial year of this study. Thanks to Professor Lisa Barcellos, Professor Ayesha Mahmud, and Professor Ellen Eisen for their invaluable input on the methodological approach in the early phases of this analysis. We are deeply saddened by the loss of our co-author, Dr. Lee Riley, who was a kind mentor, outstanding scientist, physician, researcher, and good friend. Finally, we are extremely grateful for the generosity and commitment of our study participants in Quito, without whom this work would not be possible.

Abbreviations

3GCR-EC

third-generation cephalosporin-resistant E. coli

ARG

antibiotic resistance gene

CFO

commercial food animal operation

CI

confidence interval

CLSI

Clinical and Laboratory Standards Institute

ESBL

extended-spectrum beta-lactamase

ESBL-E

extended-spectrum beta-lactamase producing Enterobacterales

ESBL-EC

extended-spectrum beta-lactamase E. coli

ExPEC

extraintestinal pathogenic E. coli

LMIC

low- and middle-income country

MLST

multilocus sequence typing

NIH

National Institutes of Health

ODK

Open Data Kit

RERI

relative excess risk due to interaction

RR

relative risk

SARS-CoV-2

Severe Acute Respiratory Syndrome Coronavirus 2

SD

standard deviation

ST

sequence type

Data Availability

Raw reads from isolates sequenced in this study are available at the NCBI Short Read Archive (SRA) under BioProject accession no. PRJNA861272. Exposure and outcome data used in epidemiological analyses are published and publicly available on Dryad (https://doi.org/10.5061/dryad.41ns1rnm7).

Funding Statement

This research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award Number R01AI135118, awarded to JG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A. 2015;112:5649–5654. doi: 10.1073/pnas.1503141112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022. doi: 10.1016/S0140-6736(21)02724-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Seiffert SN, Hilty M, Perreten V, Endimiani A. Extended-spectrum cephalosporin-resistant Gram-negative organisms in livestock: an emerging problem for human health? Drug Resist Updat. 2013;16:22–45. doi: 10.1016/j.drup.2012.12.001 [DOI] [PubMed] [Google Scholar]
  • 4.Ma F, Xu S, Tang Z, Li Z, Zhang L. Use of antimicrobials in food animals and impact of transmission of antimicrobial resistance on humans. Biosafety and Health. 2021;3:32–38. [Google Scholar]
  • 5.Centers for Disease Control and Prevention (U.S.) Antibiotic Resistance Threats in the United States, 2019. U.S. Department of Health and Human Services, Centres for Disease Control and Prevention. 2019 [Google Scholar]
  • 6.WHO publishes list of bacteria for which new antibiotics are urgently needed. Available from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed 2022 Apr 25.
  • 7.Flokas ME, Karanika S, Alevizakos M, Mylonakis E. Prevalence of ESBL-Producing Enterobacteriaceae in Pediatric Bloodstream Infections: A Systematic Review and Meta-Analysis. PLoS ONE. 2017;12:e0171216. doi: 10.1371/journal.pone.0171216 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014;9:232–238. [DOI] [PubMed] [Google Scholar]
  • 9.Ray S, Anand D, Purwar S, Samanta A, Upadhye KV, Gupta P, et al. Association of high mortality with extended–spectrum β-lactamase (ESBL) positive cultures in community acquired infections. J Crit Care. 2018;44:255–260. [DOI] [PubMed] [Google Scholar]
  • 10.Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002;162:185–190. doi: 10.1001/archinte.162.2.185 [DOI] [PubMed] [Google Scholar]
  • 11.Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol. 2006;4:36–45. doi: 10.1038/nrmicro1325 [DOI] [PubMed] [Google Scholar]
  • 12.Pallecchi L, Bartoloni A, Fiorelli C, Mantella A, Di Maggio T, Gamboa H, et al. Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America. Antimicrob Agents Chemother. 2007;51:2720–2725. doi: 10.1128/AAC.00026-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Giamarellou H. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect. 2005;11:1–16. [DOI] [PubMed] [Google Scholar]
  • 14.Hargreaves ML, Shaw KM, Dobbins G. Clonal Dissemination of Enterobacter cloacae Harboring blaKPC-3 in the Upper Midwestern United States. Antimicrob Agents Chemother. 2015;59:7723–7734. doi: 10.1128/AAC.01291-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.von Wintersdorff CJH, Penders J, van Niekerk JM, Mills ND, Majumder S, van Alphen LB, et al. Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer. Front Microbiol. 2016. doi: 10.3389/fmicb.2016.00173 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bezabih YM, Sabiiti W, Alamneh E, Bezabih A, Peterson GM, Bezabhe WM, et al. The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community. J Antimicrob Chemother. 2021;76:22–29. doi: 10.1093/jac/dkaa399 [DOI] [PubMed] [Google Scholar]
  • 17.Gilbert M, Conchedda G, Van Boeckel TP. Income Disparities and the Global Distribution of Intensively Farmed Chicken and Pigs. PLoS ONE. 2015;10:e0133381. doi: 10.1371/journal.pone.0133381 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Lowenstein C, Waters WF, Roess A, Leibler JH, Graham JP. Animal Husbandry Practices and Perceptions of Zoonotic Infectious Disease Risks Among Livestock Keepers in a Rural Parish of Quito, Ecuador. Am J Trop Med Hyg. 2016;95:1450–1458. doi: 10.4269/ajtmh.16-0485 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Silbergeld EK, Graham J, Price LB. Industrial Food Animal Production, Antimicrobial Resistance, and Human Health. Annu Rev Public Health. 2008;29:151–169. doi: 10.1146/annurev.publhealth.29.020907.090904 [DOI] [PubMed] [Google Scholar]
  • 20.Livestock production in Latin America and the Caribbean. Available from: http://www.fao.org/americas/prioridades/produccion-pecuaria/en/. Accessed 2022 Apr 25.
  • 21.Braykov NP, Eisenberg JNS, Grossman M. Antibiotic Resistance in Animal and Environmental Samples Associated with Small-Scale Poultry Farming in Northwestern Ecuador. mSphere. 2016. doi: 10.1128/mSphere.00021-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Barnes AN, Anderson JD, Mumma J, Mahmud ZH, Cumming O. The association between domestic animal presence and ownership and household drinking water contamination among peri-urban communities of Kisumu, Kenya. PLoS ONE. 2018;13:e0197587. doi: 10.1371/journal.pone.0197587 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ngure F, Gelli A, Becquey E. Exposure to livestock feces and water quality, sanitation, and hygiene (WASH) conditions among caregivers and young children: Formative research in rural Burkina Faso. Am J Trop Med Hyg. 2019;100:998–1004. doi: 10.4269/ajtmh.18-0333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kwong LH, Ercumen A, Pickering AJ, Arsenault JE, Islam M, Parvez SM, et al. Ingestion of fecal bacteria along multiple pathways by young children in rural Bangladesh participating in a cluster-randomized trial of water, sanitation, and hygiene interventions (WASH benefits). Environ Sci Technol. 2020;54:13828–13838. doi: 10.1021/acs.est.0c02606 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ngure FM, Humphrey JH, Mbuya MNN, Majo F, Mutasa K, Govha M, et al. Formative research on hygiene behaviors and geophagy among infants and young children and implications of exposure to fecal bacteria. Am J Trop Med Hyg. 2013;89:709–716. doi: 10.4269/ajtmh.12-0568 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lateef A, Oloke JK, Gueguimkana EB. The prevalence of bacterial resistance in clinical, food, water and some environmental samples in Southwest Nigeria. Environ Monit Assess. 2005;100:59–69. doi: 10.1007/s10661-005-7062-7 [DOI] [PubMed] [Google Scholar]
  • 27.Kalter HD, Gilman RH, Moulton LH, Cullotta AR, Cabrera L, Velapatiño B. Risk factors for antibiotic-resistant Escherichia coli carriage in young children in Peru: community-based cross-sectional prevalence study. Am J Trop Med Hyg. 2010;82:879–888. doi: 10.4269/ajtmh.2010.09-0143 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bartley PS, Moretto VT, Silva LK, Cordeiro SM, Reis MG, Blanton RE, et al. THE ASSOCIATION BETWEEN FECAL CONTAMINATION AND ENVIRONMENTAL ANTIBIOTIC RESISTANCE IN RURAL BRAZIL. In: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. AMER SOC TROP MED & HYGIENE 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA, p 26–27. 2017. [Google Scholar]
  • 29.Purohit MR, Chandran S, Shah H, Diwan V, Tamhankar AJ, Stålsby Lundborg C. Antibiotic resistance in an Indian rural community: A “one-health” observational study on commensal coliform from humans, animals, and water. Int J Environ Res Public Health. 2017;14:386. doi: 10.3390/ijerph14040386 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zambrano LD, Levy K, Menezes NP, Freeman MC. Human diarrhea infections associated with domestic animal husbandry: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2014;108:313–325. doi: 10.1093/trstmh/tru056 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Bauza V, Byrne DM, Trimmer JT, Lardizabal A, Atiim P, Asigbee MAK, et al. Child soil ingestion in rural Ghana–frequency, caregiver perceptions, relationship with household floor material and associations with child diarrhoea. Trop Med Int Health. 2018;23:558–569. doi: 10.1111/tmi.13050 [DOI] [PubMed] [Google Scholar]
  • 32.Penakalapati G, Swarthout J, Delahoy MJ, McAliley L, Wodnik B, Levy K, et al. Exposure to Animal Feces and Human Health: A Systematic Review and Proposed Research Priorities. Environ Sci Technol. 2017;51:11537–11552. doi: 10.1021/acs.est.7b02811 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kurowski KM, Marusinec R, Amato HK, Saraiva-Garcia C, Loayza F, Salinas L, et al. Social and Environmental Determinants of Community-Acquired Antimicrobial-Resistant Escherichia coli in Children Living in Semirural Communities of Quito, Ecuador. Am J Trop Med Hyg. 2021;105:600–610. doi: 10.4269/ajtmh.20-0532 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Marusinec R, Kurowski KM, Amato HK, Saraiva-Garcia C, Loayza F, Salinas L, et al. Caretaker knowledge, attitudes, and practices (KAP) and carriage of extended-spectrum beta-lactamase-producing E. coli (ESBL-EC) in children in Quito, Ecuador. Antimicrobial Resistance & Infection Control. 2021. doi: 10.1186/s13756-020-00867-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Hijazi SM, Fawzi MA, Ali FM, Abd El Galil KH. Multidrug-resistant ESBL-producing Enterobacteriaceae and associated risk factors in community infants in Lebanon. J Infect Dev Ctries. 2016;10:947–955. doi: 10.3855/jidc.7593 [DOI] [PubMed] [Google Scholar]
  • 36.Herindrainy P, Randrianirina F, Ratovoson R, Ratsima Hariniana E, Buisson Y, Genel N, et al. Rectal carriage of extended-spectrum beta-lactamase-producing gram-negative bacilli in community settings in Madagascar. PLoS ONE. 2011;6:e22738. doi: 10.1371/journal.pone.0022738 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Pebesma E, Bivand R, Racine E. sf: Simple Features for R. 2021. [Google Scholar]
  • 38.R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria; 2020. [Google Scholar]
  • 39.Amato HK, Wong NM, Pelc C, Taylor K, Price LB, Altabet M, et al. Effects of concentrated poultry operations and cropland manure application on antibiotic resistant Escherichia coli and nutrient pollution in Chesapeake Bay watersheds. Sci Total Environ. 2020;735:139401. doi: 10.1016/j.scitotenv.2020.139401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lehner B, Verdin K, Jarvis A. New global hydrography derived from spaceborne elevation data. Eos. 2008;89:93. [Google Scholar]
  • 41.QGIS Association. Qgis.org. In: QGIS Geographic Information System. Available from: http://www.qgis.org. 2022.
  • 42.Hartung C, Lerer A, Anokwa Y, Tseng C, Brunette W, Borriello G. Open data kit: tools to build information services for developing regions. In: Proceedings of the 4th ACM/IEEE International Conference on Information and Communication Technologies and Development. New York, NY, USA: Association for Computing Machinery; 2010. p 1–12. [Google Scholar]
  • 43.Lautenbach E, Bilker WB, Tolomeo P, Maslow JN. Impact of diversity of colonizing strains on strategies for sampling Escherichia coli from fecal specimens. J Clin Microbiol. 2008;46:3094–3096. doi: 10.1128/JCM.00945-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.(2018) Performance standards for antimicrobial susceptibility testing; 27th informational supplement. M100-S28. Wayne, PA. [Google Scholar]
  • 45.Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–2120. doi: 10.1093/bioinformatics/btu170 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Bankevich A, Nurk S, Antipov D. SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–477. doi: 10.1089/cmb.2012.0021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67:2640–2644. doi: 10.1093/jac/dks261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Larsen MV, Cosentino S, Rasmussen S. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol. 2012;50:1355–1361. doi: 10.1128/JCM.06094-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Alikhan N-F, Zhou Z, Sergeant MJ, Achtman M. A genomic overview of the population structure of Salmonella. PLoS Genet. 2018;14:e1007261. doi: 10.1371/journal.pgen.1007261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Salinas L, Loayza F, Cárdenas P, Saraiva C, Johnson TJ, Amato H, et al. Environmental spread of extended spectrum beta-lactamase (ESBL) producing Escherichia coli and ESBL genes among children and domestic animals in Ecuador. Environ Health Perspect. 2021;129:27007. doi: 10.1289/EHP7729 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Lee DS, Choe H-S, Kim HY. Role of age and sex in determining antibiotic resistance in febrile urinary tract infections. Int J Infect Dis. 2016;51:89–96. doi: 10.1016/j.ijid.2016.08.015 [DOI] [PubMed] [Google Scholar]
  • 52.Wickham H, François R, Henry L, Müller K, RStudio (2021) dplyr: A Grammar of Data Manipulation. [Google Scholar]
  • 53.Yoshida K, Bartel A, Chipman JJ, Bohn J, McGowan LD, Barrett M, et al. gbouzill (2020) tableone: Create “Table 1” to Describe Baseline Characteristics with or without Propensity Score Weights. [Google Scholar]
  • 54.Wickham H, Chang W, Henry L, Pedersen TL, Takahashi K, Wilke C, et al. RStudio (2021) ggplot2: Create Elegant Data Visualisations Using the Grammar of Graphics. [Google Scholar]
  • 55.Halekoh U, Højsgaard S, Yan J. The R Package geepack for Generalized Estimating Equations. J Stat Softw. 2006;15(2):1–11. [Google Scholar]
  • 56.Hothorn T, Bretz F, Westfall P. Simultaneous Inference in General Parametric Models. Biom J. 2008;50:346–363. doi: 10.1002/bimj.200810425 [DOI] [PubMed] [Google Scholar]
  • 57.Fox J, Weisberg S. An R Companion to Applied Regression. 2019. [Google Scholar]
  • 58.Manges AR, Geum HM, Guo A, Edens TJ, Fibke CD, Pitout JDD. Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages. Clin Microbiol Rev. 2019. doi: 10.1128/CMR.00135-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Nadimpalli M, Rinsky JL, Wing S. Persistence of livestock-associated antibiotic-resistant Staphylococcus aureus among industrial hog operation workers in North Carolina over 14 days. Occup Environ Med. 2015;72:90–99. doi: 10.1136/oemed-2014-102095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Nadimpalli M, Stewart JR, Pierce E. Livestock-Associated, Antibiotic-Resistant Staphylococcus aureus Nasal Carriage and Recent Skin and Soft Tissue Infection among Industrial Hog Operation Workers. PLoS ONE. 2016;11:e0165713. doi: 10.1371/journal.pone.0165713 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Nadimpalli ML, Stewart JR, Pierce E. Face mask use and persistence of livestock-associated Staphylococcus aureus nasal carriage among industrial hog operation workers and household contacts, USA. Environ Health Perspect. 2018;126:127005. doi: 10.1289/EHP3453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.van den Bogaard AE, Stobberingh EE. Epidemiology of resistance to antibiotics. Links between animals and humans. Int J Antimicrob Agents. 2000;14:327–335. doi: 10.1016/s0924-8579(00)00145-x [DOI] [PubMed] [Google Scholar]
  • 63.Dorado-García A, Dohmen W, Bos MEH, Verstappen KM, Houben M, Wagenaar JA, et al. Dose-response relationship between antimicrobial drugs and livestock-associated MRSA in pig farming. Emerg Infect Dis. 2015;21:950–959. doi: 10.3201/eid2106.140706 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Li J, Bi Z, Ma S. Inter-host Transmission of Carbapenemase-Producing Escherichia coli among Humans and Backyard Animals. Environ Health Perspect. 2019;127:107009. doi: 10.1289/EHP5251 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Hedman HD, Eisenberg JNS, Trueba G, Rivera DLV, Herrera RAZ, Barrazueta JV, et al. Impacts of small-scale chicken farming activity on antimicrobial-resistant Escherichia coli carriage in backyard chickens and children in rural Ecuador. One Health. 2019;8:100112. doi: 10.1016/j.onehlt.2019.100112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Addis Z, Kebede N, Worku Z, Gezahegn H, Yirsaw A, Kassa T. Prevalence and antimicrobial resistance of Salmonella isolated from lactating cows and in contact humans in dairy farms of Addis Ababa: a cross sectional study. BMC Infect Dis. 2011;11:222. doi: 10.1186/1471-2334-11-222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Riccobono E, Pallecchi L, Mantella A, Bartalesi F, Zeballos IC, Trigoso C, et al. Carriage of antibiotic-resistant Escherichia coli among healthy children and home-raised chickens: a household study in a resource-limited setting. Microb Drug Resist. 2012;18:83–87. doi: 10.1089/mdr.2011.0003 [DOI] [PubMed] [Google Scholar]
  • 68.Karanika K. Arvanitis Fecal Colonization With Extended-spectrum Beta-lactamase–Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and …. Rev. Infect. Dis. [DOI] [PubMed] [Google Scholar]
  • 69.Villegas MV, Blanco MG, Sifuentes-Osornio J, Rossi F. Increasing prevalence of extended-spectrum-betalactamase among Gram-negative bacilli in Latin America: 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Braz J Infect Dis. 2011;15:34–39. [PubMed] [Google Scholar]
  • 70.Leão C, Clemente L, Moura L, Seyfarth AM, Hansen IM, Hendriksen RS, et al. Emergence and Clonal Spread of CTX-M-65-Producing Escherichia coli From Retail Meat in Portugal. Front Microbiol. 2021;12:653595. doi: 10.3389/fmicb.2021.653595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Zheng H, Zeng Z, Chen S. Prevalence and characterisation of CTX-M β-lactamases amongst Escherichia coli isolates from healthy food animals in China. Int J Antimicrob Agents. 2012;39:305–310. [DOI] [PubMed] [Google Scholar]
  • 72.Park H, Kim J, Ryu S, Jeon B. Predominance of blaCTX-M-65 and blaCTX-M-55 in extended-spectrum β-lactamase-producing Escherichia coli from raw retail chicken in South Korea. J Glob Antimicrob Resist. 2019;17:216–220. [DOI] [PubMed] [Google Scholar]
  • 73.Ho C, Lai L. Extensive dissemination of CTX-M-producing Escherichia coli with multidrug resistance to “critically important” antibiotics among food animals in Hong Kong, 2008. –10. J At Mol Phys. [DOI] [PubMed] [Google Scholar]
  • 74.Cormier A, Zhang PLC, Chalmers G, Weese JS, Deckert A, Mulvey M, et al. Diversity of CTX-M-positive Escherichia coli recovered from animals in Canada. Vet Microbiol. 2019;231:71–75. doi: 10.1016/j.vetmic.2019.02.031 [DOI] [PubMed] [Google Scholar]
  • 75.Salinas L, Cárdenas P, Johnson TJ, Vasco K, Graham J, Trueba G. Diverse Commensal Escherichia coli Clones and Plasmids Disseminate Antimicrobial Resistance Genes in Domestic Animals and Children in a Semirural Community in Ecuador. mSphere. 2019. doi: 10.1128/mSphere.00316-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Waters WF, Baca M, Graham JP, Butzin-Dozier Z, Vinueza L. Antibiotic use by backyard food animal producers in Ecuador: a qualitative study. BMC Public Health. 2022;22:685. doi: 10.1186/s12889-022-13073-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Brueggemann R. Shaw Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19. Lancet Digit. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Hedman HD, Zhang L, Trueba G. Spatial Exposure of Agricultural Antimicrobial Resistance in Relation to Free-Ranging Domestic Chicken Movement Patterns among Agricultural Communities in Ecuador. Am J Trop Med Hyg. 2020;103:1803–1809. doi: 10.4269/ajtmh.20-0076 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Cárdenas M, Grijalva CJ, de la Torre S. Free-Roaming Dog Surveys in Quito, Ecuador: Experiences, Lessons Learned, and Future Work. Front Vet Sci. 2021;8:766348. doi: 10.3389/fvets.2021.766348 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Saavedra-Aracena L, Grimm-Seyfarth A, Schüttler E. Do dog-human bonds influence movements of free-ranging dogs in wilderness? Appl Anim Behav Sci. 2021;241:105358. [Google Scholar]
  • 81.Montero L, Irazabal J, Cardenas P, Graham JP, Trueba G (2021) Extended-spectrum beta-lactamase producing-Escherichia coli isolated from irrigation waters and produce in Ecuador. Front Microbiol doi: 10.3389/fmicb.2021.709418 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Gupta A, Ampofo K, Rubenstein D, Saiman L. Extended Spectrum β Lactamase-producing Klebsiella pneumoniae Infections: a Review of the Literature. J Perinatol. 2003;23:439–443. [DOI] [PubMed] [Google Scholar]
  • 83.Lam Y, Fry JP, Nachman KE (2019) Applying an environmental public health lens to the industrialization of food animal production in ten low- and middle-income countries. Globalization and Health 10.1186/s12992-019-0479-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Leet JK, Volz DC. Improving waste management strategies for small livestock farms. Environ Sci Technol. 2013;47:11940–11941. doi: 10.1021/es404078b [DOI] [PubMed] [Google Scholar]
  • 85.World Health Organization WHO guidelines on use of medically important antimicrobials in food-producing animals. World Health Organization. 2017 [PubMed] [Google Scholar]
  • 86.Nobrega DB, Tang KL, Caffrey NP, De Buck J, Cork SC, Ronksley PE et al. Prevalence of antimicrobial resistance genes and its association with restricted antimicrobial use in food-producing animals: a systematic review and meta-analysis. J Antimicrob Chemother. 2021;76:561–575. doi: 10.1093/jac/dkaa443 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Philippa C Dodd

22 Aug 2022

Dear Dr Amato,

Thank you for submitting your manuscript entitled "Risk factors for extended-spectrum beta-lactamase (ESBL) producing E. coli carriage among children in a food animal producing region of Quito, Ecuador" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff as well as by an academic editor with relevant expertise and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Aug 24 2022 11:59PM.

Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at plosmedicine@plos.org if you have any queries relating to your submission.

Kind regards,

Philippa

Philippa Dodd, MBBS MRCP PhD

Senior Editor

PLOS Medicine

Decision Letter 1

Philippa C Dodd

7 Dec 2022

Dear Dr. Amato,

Thank you very much for submitting your manuscript "Risk factors for extended-spectrum beta-lactamase (ESBL) producing E. coli carriage among children in a food animal producing region of Quito, Ecuador" (PMEDICINE-D-22-02768R1) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Dec 28 2022 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Philippa Dodd, MBBS MRCP PhD

PLOS Medicine

plosmedicine.org

-----------------------------------------------------------

Requests from the editors:

GENERAL

Please respond to all editor and reviewer comments below, in full.

Please number each line of the manuscript starting with 1 on the first line of page 2 and in continuous sequence thereafter.

Please ensure that the study is reported according to the STROBE guideline, and include the completed STROBE checklist as Supporting Information. Please add the following statement, or similar, to the Methods: "This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist)."

The STROBE guideline can be found here: http://www.equator-network.org/reporting-guidelines/strobe/

When completing the checklist, please use section and paragraph numbers, rather than page numbers.

ABSTRACT

Abstract methods and findings:

Please include the actual amounts and/or absolute risk(s) of relevant outcomes (including NNT or NNH where appropriate), not just relative risks or correlation coefficients. (example for absolute risks: PMID: 28399126).

Where 95% CIs are reported please also report p-values.

Suggest for clarity that statistical information is defined clearly perhaps with abbreviations (e.g. 95% CI) at each reporting, as you have done in the main manuscript, as opposed to just once in full.

Please ensure that all numbers presented in the abstract are present and identical to numbers presented in the main manuscript text.

It may be helpful to elaborate on the details of the study design including for clarity some of the different risk factors (or categories of risk factor) investigated. The reader doesn’t learn of any until the significant results are reported. Suggest including the number of participants (as well as the sample number), length of follow-up/number of visits and more clearly defining the region (see also statistical reviewer comments) and use of animals for subsistence farming Vs trade

Suggest moving the following sentence “We used multivariable log-binomial regression models to estimate relative risks (RR) of 3GCR-EC and ESBL-EC carriage.” To follow the description of the study before the results are presented.

Please include the important dependent variables that are adjusted for in the analyses.

In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study's methodology

Abstract Conclusions:

Please address the study implications without overreaching what can be concluded from the data; the phrase "In this study, we observed ..." may be useful.

Please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions.

Please avoid vague statements such as "these results have major implications for policy/clinical care". Mention only specific implications substantiated by the results.

Please avoid assertions of primacy ("We report for the first time....")

AUTHOR SUMMARY

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

METHODS and RESULTS

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c) In either case, changes in the analysis-- including those made in response to peer review comments-- should be identified as such in the Methods section of the paper, with rationale.

For all observational studies we ask that the following is clearly indicated in the manuscript text:

(1) the specific hypotheses you intended to test,

(2) the analytical methods by which you planned to test them,

(3) the analyses you actually performed, and

(4) when reported analyses differ from those that were planned, transparent explanations for differences that affect the reliability of the study's results. If a reported analysis was performed based on an interesting but unanticipated pattern in the data, please be clear that the analysis was data-driven.

Page 11 para 3: please ensure that where you report percentages that the numerators and denominators used to derive them are clearly reported. In the paragraphs above whole numbers are reported but it is a bit arduous to the reader to go back and forth for reference.

FIGURES

Please consider avoiding the use of red or green to make the figures more accessible to those with colour blindness

Figure 1: Please confirm that the appropriate usage rights apply to the use of this map. Please see our guidelines for map images:

https://journals.plos.org/plosmedicine/s/figures#loc-maps

Figure 2: PLOS medicine usually advises against the use of pie charts but in this specific case we agree with the methodological reviewer that they serve their purpose here very nicely

Figures 3 and 4: Please clearly indicate the meaning of lines and dots on the plots. Please clearly indicate whether the analyses are adjusted and in the figure captions what factors they are adjusted for. Where adjusted analyses are presented, please also present unadjusted analyses. It would be helpful to the reader to list the numerical values for RR and 95% CIs in a column next to the plots. In addition, where you report 95% CIs please also report p-values and in the figure caption please define the test used to derive them

Please ensure all abbreviations for statistical reporting are defined e.g RR and CI

TABLES

For the main outcome measures presented in table 3 and 4, to help facilitate transparency of data reporting please indicate in the column headers that these analyses are adjusted and also provide the unadjusted analyses for comparison

SUPPLEMENTARY FIGURES AND TABLES

Please check carefully throughout and ensure all abbreviations are defined (for example SES, ESBL).

Where you report 95% CIs please also ensure p-values are reported

Where adjusted analyses are reported please clearly indicate which factors are adjusted for, in the caption, and also present the unadjusted analyses for comparison.

DISCUSSION

Please present and organize the Discussion as follows: a short, clear summary of the article's findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

REFERENCES

Please use the "Vancouver" style for reference formatting, and see our website for other reference guidelines

https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references

Citations should be in square brackets, and preceding punctuation [1,3,5,7] or [1-4,7]. Please note the absence of spaces between citations.

Journal name abbreviations should be those found in the National Center for Biotechnology Information (NCBI) databases.

In the bibliography, please list up to but no more than 6 names followed by et al where more than 6 authors contribute to a study.

PARACHUTE RESEARCH

We note that you conducted research or obtained samples in a foreign country. Did you consider including a local author as first or last author? If not, we recommend that you consider doing so in line with ICMJE's authorship requirements (https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html). PLOS has a parachute research policy which aims to promote collaboration and inclusivity in global health research. You are required to complete PLOS’ questionnaire on inclusivity in global research and submit it with your revised paper. The policy and questionnaire can be found at https://journals.plos.org/plosone/s/best-practices-in-research-reporting.

DECLARATION STATEMENTS

Please remove these from the end of the manuscript and place in the manuscript submission form only. The ethics statement can be placed in the methods section.

SOCIAL MEDIA

In the event that your paper is published, to help us extend the reach of your research, please provide any Twitter handle(s) that would be appropriate to tag, including your own, your coauthors’, your institution, funder, or lab. Please respond to this email with any handles you wish to be included when we tweet this paper.

Comments from the reviewers:

Reviewer #1: This manuscript describes the results of an observational study on environmental exposure by commercial and small-scale food animal production and risk factors for ESBL-producing E. coli and third-generation cephalosporin-resistant E. coli carriage in children in Ecuador. It is important that this kind of studies are performed in low- and middle-income countries to increase the knowledge and to identify potential measures that can be taken to reduce the risks for ESBL carriage in children. Furthermore, it is a nicely designed and well-written study with repeated measurements per household. I do have some questions for the authors though.

Major comments:

1. Why were the selected E. coli isolates frozen and thawed again before susceptibility and phenotypic ESBL-production testing was performed? Do the authors think this may have influenced the results they found compared to immediate susceptibility and phenotypic ESBL-production testing?

2. Why were the analyses performed on isolate level, and not on child-level (child being colonized or not)? Did the authors check for results on child-level? I am also curious on parish level how many kids were colonized, and the mean/sd number of isolates on child-level per parish.

3. Hoe were the isolates selected that were sequenced? It is not mentioned in the Methods section how this selection was done.

4. Page 11 second paragraph: 1,677 child fecal samples from 594 households remained. Is it then correct that the 1,677 fecal samples were taken from 594 children? Also, I don't get how the numbers mentioned in this paragraph add up to 1,940 observations: is that 904 3GCR-EC isolated in children plus 1,060 3GCR-EC in animals (=1,964)? Please clarify.

5. A lot of different statistical analyses and tests were performed. However, I did not read anything about corrections made for multiple testing which I think is very appropriate in this case.

6. Table 1: Is it correct that none of the household food animals received antibiotics in the 5th data collection cycle? In the other cycles it ranged from 9.5-26.4%, so this is a big difference. Do the authors have an explanation for this finding?

7. Longitudinal findings in individual children, did the authors analyse whether the same children carried the same ST E. coli and gene during follow-up data collection cycles? Of course, this is only possible for children who participated >1 cycle. This would also be very interesting to see, whether there was a new or new type of colonization or whether it is still the same type. In the last case, it is could be a non-cleared colonization or a repeated exposure/colonization.

8. Table S6: high percentage of OXA genes in Tababela compared to all other parishes, explanation for this difference.

9. Figure 2/Table S8: most of the commonly detected CTX-M-type genes are both found in parishes with low- and high-CFOs. For example, CTX-M-15 represents 50% of the CTX-M genes found in Tababela with low CFO and ≈55% in El Quinche with high CFO. Are there any other suspected common sources that the authors could think of which may explain these findings?

10. Results page 14/15 and 1st paragraph of the Discussion. All results with an RR >1 are presented as having an increased risk, but some of them are not statistically significant since the 1 is included in the 95% CI. In my opinion this should be mentioned more explicitly when results are or are not statistically significant. For example: "However, the combination of owning household food animals and living <1.5 km from the nearest commercial operation was associated with an increased risk in 3GCR-EC carriage (RR: 1.15; 95% CI: 0.97, 1.33) compared to those without food animals who lived further from commercial food animal operations". It is presented like a significant increased risk, but it is not. Also, the last line of page 14: "chicken ownership (RR: 1.10; 95% CI: 0.98, 1.24), and rarely/never washing hands after contact with animals (RR: 1.15; 95% CI: 0.98, 1.34)". These are non-significant risk factors while the first two factors mentioned in this sentence are not. I would not mention them separately as these non-significant factors can be found in the Tables. Finally, this non-significant "rarely/never washing hands after contact with animals" is even mentioned in the abstract together with significant results.

11. Table 4: The RR of in children without household food animals with distance to the nearest farm <1.5km away seems to be protective (although not statistically significant) compared to >=1.5km away. Any explanation for that?

12. Page 17 line 2: Were animal samples and child samples matched? So were the same ST's and genes identified in children and animals of the same household? And were analyses performed on these matched isolates?

Minor comments:

1. Page 3 last paragraph: "ESBL-producing enterobacteriaceae infections". "Enterobacteriaceae" are renamed as "Enterobacterales".

2. Table S3: The column name of the second column is 'H', I think this reflects the number of households. The legend says it should read 'HH'. Please adapt them consistent.

3. Table S10: I suggest to present the RR and 95% CI with 2 decimals (like in all other Tables) and the P-values with 3 decimals instead of 4.

Reviewer #2: Dear editor,

Thank you for asking me to review this article. I believe the topic fits Plos Medicine really well. Livestock is already known to be a reservoir for antimicrobial resistant bacteria and livestock-human transmission is documented as well. However, most of the studies are conducted in the Western world. I believe it is very interesting to investigate the risk of animal food production for ESBL carriage in humans in other parts of the world. Therefore, I do believe that after improvement this manuscript can add valuable information to the topic of human antimicrobial carriage. However, I have some major concerns regarding the data analysis performed, interpretation of the results and following conclusions stated. Therefore, I would advise major revisions.

I would recommend that the authors check the data analysis and thoroughly read through their manuscript again and rewrite parts of it and also reduce the length of the manuscript. In the section "Comments to the authors" I also commented in more detail regarding abovementioned aspects.

Comments to the authors

I agree with the authors that it is very important to investigate livestock as a risk factor for human carriage of antimicrobial resistant bacteria (or genes) in low and middle income countries, therefore I stress the importance of the topic. However, I have some concerns regarding certain aspects (mainly your data analysis and discussion) of the manuscript. Moreover, I believe you can shorten the manuscript. Below you will find some comments in more detail.

Abstract

Page 2, Conclusions: although I understand the reasoning of what is stated in these conclusions, I don't think this conclusion aligns well with the study conducted. Risk factors for carriage were under investigation, not policies and interventions to curb the spread.

Introduction

I find the introduction too long. Every paragraph should be shortened. I think the order of paragraphs can be improved

First paragraph, first sentence: I don't understand what you state. Contamination with what? You might consider deleting this first sentence.

First paragraph, ref Seifert et al. 2013: There is more recent work done that you can cite. I would also use more references for such a statement.

First paragraph, last sentence: Please specify which communities. Moreover, although livestock-human transmission is important, but I would mention human-human transmission as background information as well.

Second paragraph: this part described the urgency and importance. I would place this paragraph first. This is the reason why you want to investigate risk factors for this human carriage.

Third and fourth paragraph can be combined.

Methods

The first paragraph could use the subheading 'study design'. I think the section on data analyses is hard to follow. I would suggest the authors to be more clear and precise. A figure might help to visualize it.

Page 5: What is the reasoning for the inclusion criteria 'child between 6 months and 5 years'?

Page 6, 'Density…..(Amato et al. 2020)': This is background information/interpretation and should not be discussed in method section, but in introduction and/or discussion.

Page 7, outcome assessment: What do you mean by animal that were present at the household? Only domestic animals? Or food production animals (backyard farming) as well?

Page 9, statistical analyses: How did you account for potential interaction? What do you mean by three different models?

What do you mean by 'using cut-points ….. policy relevance'?

How where the results from the animal derived isolates used in the models?

What do you mean by assessed at the isolate level? Did you model at the isolate level? I would say it makes sense to model at the child level (= sample level).

Results

I think the results section can be shorter in general. Lot of percentage and gene types are described, which can easily be seen in the Table. I would focus on highlights in text.

Page 10/11: I find the figure S2 helpful in understanding. However, from both the text and the figure I cannot interpret how many households did how many repeats? Please provide this information?

Page 11: What are the 1940 observations? It looks like you are modeling at the isolate level. But exposures are at the child sampling moment level (i.e. each stool sample is a single observation).

Page 12, Food Animal Production & Domestic Animals, first paragraph: what is the rationale for only mentioning the first four cycles of data collection to describe the distance to the number of farms?

Page 14, Risk Factors for 3GCR-EC: I am slightly confused by these results. You state that children with > 5 commercial food animal operations in a 5-km radius of their household had a higher risk of 3GCR-EC carriage. However, in table 3 I only see the results of the stratified analyses. Without stratifying, what is the effect? In order to understand any effect modification, I would like to see the overall results as well. Why is a different cut-of chosen for the no of operation in an 5 km radius in the analysis among those with household food animals. Also, I am missing the sizes of the strata.

Discussion

I think most of the paragraphs in the discussion can be shortened, it often takes a long read before you reach your message. The paragraph on policy advice should be deleted in my opinion. This was not your research question in the first place, and I think your results should be used for policy if applicable, but policy is not supposed to be made by researchers.

Page 16, second paragraph: I do not think that the epidemiological studies have shown a clear link between food animal production and community-acquired antibiotic-resistant infections. Instead it is associated with carriage of ABR bacteria.

Page 17, top of page: I agree that repeated measurements are essential to investigate this association, but from the manuscript the range of number of repeated measurements is not clear.

Also, you mention your One Health design, what do you mean by that? I read that you samples animals (domestic or commercial as well?) at the same household, but I don't see how you used it in your analysis.

Page 17, paragraph on AB use: I find this paragraph hard to follow. Please be clear on what is from the other study and what is from your study.

What do you mean by indirect curbing of infectious diseases in animals by the pandemic?

Page 18, bottom of the page: I don't agree with your analysis at the isolate level (see comments on methods and results)

Page 19, paragraph on prevalence. I would move this paragraph up, since it is a rather important finding.

Page 20, gene types found in children: I understand that the gene types found are similar as in livestock animals. What are the main types in the general population lesser in contact with animals? That should give a more or less control situation.

Page 20: delete the paragraph on policy and please remove the policy regarding statements also from your conclusions and abstract.

Reviewer #3: This is a potentially interesting study on a relevant topic. However, it is presented as an epidemiological study, which highlights a number of shortcomings in the design and reporting in the paper. The study mostly uses proxy indicators of AMR exposure, or caregiver reported indicators of hygiene and child behaviour. Any observed associations do not really shed light on the pathways of AMR transmission.

The key limitation is the lack of assessment of antibiotic resistant E. coli in the majority of the exposures that are reported.

Specific comments:

Assessment of risk factors is done using proxy measures (e.g. geographical distance and concentration of commercial livestock/animal farms) without any direct measures of antibiotic resistant bacteria, genes or antibiotic residues and there is no information presented on whether these commercial premises used antibiotics, which antibiotics were used, and/or gut colonisation with ARB in the commercial animals.

Similarly, the proxy measure of proximity to drainage channels does not provide direct evidence of exposure to ARB/ARG. No analysis of water samples from these drainage channels were taken or analysed.

Proxy measures can only provide weak inferences about relationships (or not) between environmental exposures and human colonisation with ARB.

'The primary outcomes, 3GCR-EC and ESBL-EC carriage, were assessed at the isolate level' There is no clear rationale for why the study reports AMR at the isolate level rather than the individual child (or household animal) level, especially as the methods changed part way through the study (extracting 5 E. coli isolates in the early rounds, and only 1 isolate in later rounds).

As this is intended as an epidemiological study, why is the analysis not at the individual child level, with the denominator as the total number of individuals, taking into account repeat measures?

If the study places importance on caregiver-reported hygiene and reported infant behaviours (child handwashing, contact with animals or pets) as risk factors for child colonisation then some validity of these measures is needed. These types of indicators have poor validity & reliability in most contexts. A reporting window of child pet contact in the last 3 months (yes or no) is also a very crude indicator.

The key limitation is the lack of assessment of antibiotic resistant E. coli in the majority of the exposures that are reported.

Other suggestions/queries.

The authors make it clear that the number of isolates per sample changed part way. However it is not clear why the analysis did not use one isolate per sample throughout all the analysis to remove the bias, then there would not be the need for a sensitivity analysis.

Some of the key information for the study seems to be in supplementary tables e.g. point prevalence of child ESBL-EC colonisation at each survey, ranging from 7% to 16%, average 11%, which seems relatively low. This would merit reporting in the results and discussion.

Samples were left with participants/households for 24 hours, how was it ensured that these were actually stored in fridges or on ice?

Reviewer #4: See attachment

Michael Dewey

Any attachments provided with reviews can be seen via the following link:

[LINK]

Attachment

Submitted filename: amato.pdf

Decision Letter 2

Philippa C Dodd

15 Jun 2023

Dear Dr. Amato,

Thank you very much for re-submitting your manuscript "Risk factors for extended-spectrum beta-lactamase (ESBL) producing E. coli carriage among children in a food animal producing region of Ecuador" (PMEDICINE-D-22-02768R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and it was also seen again by 3 reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.  

We look forward to receiving the revised manuscript by Jun 22 2023 11:59PM.   

Sincerely,

Philippa Dodd, MBBS MRCP PhD

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

GENERAL

Please respond to all editor and reviewer comments detailed below, in full.

TITLE

Please revise your title according to PLOS Medicine's style. Your title must be nondeclarative and not a question. It should begin with main concept if possible. "Effect of" should be used only if causality can be inferred, i.e., for an RCT. Please place the study design ("A randomized controlled trial," "A retrospective study," "A modelling study," etc.) in the subtitle (ie, after a colon). Please include the country of origin (Ecuador) in the title.

AUTHOR SUMMARY

Thank you for including an author summary which reads very nicely but is missing some detail. Please see the information under each of the headings below and revise accordingly (specifically, sample sizes and limitations are notably absent in the current version). Please keep in mind that the summary should consist of 2-3 succinct bullet points under each heading:

• Why Was This Study Done? Authors should reflect on what was known about the topic before the research was published and why the research was needed.

• What Did the Researchers Do and Find? Authors should briefly describe the study design that was used and the study’s major findings. Do include the headline numbers from the study, such as the sample size and key findings.

• What Do These Findings Mean? Authors should reflect on the new knowledge generated by the research and the implications for practice, research, policy, or public health. Authors should also consider how the interpretation of the study’s findings may be affected by the study limitations. In the final bullet point of ‘What Do These Findings Mean?’, please describe the main limitations of the study in non-technical language.

INTRODUCTION

Suggest moving lines 110-113 ending ‘…mortality [7–10].’ to paragraph 1, line 98 preceding, ‘Anti-biotic resistant bacteria’

Suggest new paragraph at line 104 sentence beginning, ‘With the rapid…’ and combing with sentence at line 113 beginning asymptomatic carriage.

Line 126 – please use one or the other of the two in-text reference callouts.

Line 134 – please change ‘feces’ to ‘faeces’

METHODS and RESULTS

Please also see statistical reviewer comments (reviewer #4) below.

In reference to reviewer #4 comments (please see below) please clarify how the sample size was determined.

Line 170 – please state if consent was written or oral

DISCUSSION

Please begin the introduction with a short clear summary of the article’s findings.

Line 512 - please revise to read SARS-CoV-2 also at line 560, please check and amend throughout.

SUPPORTING INFORMATION

Figure S1 – please see statistical reviewer (#4) comments below.

REFERENCES

Throughout, for in-text reference callouts, please remove spaces from between citations. For example, line 100 should read ‘[2,3]’ as opposed to ‘[2, 3]’.

SOCIAL MEDIA

If not already done so, to help us extend the reach of your research, please detail any Twitter handles you wish to be included when we tweet this paper (including your own, your coauthors’, your institution, funder, or lab) in the manuscript submission form when you re-submit the manuscript.

Comments from Reviewers:

Reviewer #1: The revised manuscript has improved considerably and all the points I raised have been answered appropriately.

A few additional very minor suggestions from my side:

- Line 139: I would not only say that risks of "antibiotic-resistant and ESBL-E infections" are urgently needed to be quantified, but also include carriage here, since this is what the main objective of the study and this data is also still sparce from LMICs. Adapt "antibiotic-resistant and ESBL-E infections" to "antibiotic-resistant and ESBL-E carriage and infections". I would also consider to include this to line 459 and the conclusion (line 604).

- Line 126: reference 18 is included twice.

- Line 439: change "0.1080" into "0.108".

- Line 554: "enterobacteriales" should read "Enterobacterales".

Reviewer #2: I think the manuscript has improved in terms of length and clarity. However, some of my bigger concerns remain partially. Below, you will find my comments in more detail. I would like to stress that I don't understand that the authors decided to stick with the analysis on isolate level instead of analyzing on the individual level (as raised by almost all reviewers).

Introduction

I think the introduction has improved in its focus and it is more concise. However, I think the line in the first two paragraphs is still somewhat shaky. I don't understand some of the choices made in the order of the addressed background information. It switches a few times from ABR to ESBL and back. The same goes for health impact (addressed in both paragraphs). All information is relevant, but can be improved in ordering.

Materials and Methods

In the inclusion criteria you mention the consent of the caregiver as the third criteria. I would say it is a given that you need consent. I would just make a statement expressing that consent was given by the caretakers for al study participants (or any other covering phrase).

In the statistical analyses it is not stated at what level the outcome is (isolate level, which I still disagree on).

You described a sensitivity analysis with only the first isolate. I would say the same should have been done for the prevalence of carriage (since the sensitivity for finding a positive results is higher when taking more parallel observations per individual). Or at least discuss the impact of a different number of isolates between individuals.

Results

This part has changed massively. However, I still am confused sometimes about the numbers. In line 332-334 is stated how many isolates were collected from how many children from how many households. By including the number of isolates where cephalosporin resistant it get's less clear. I would not put in outcome results mixed with output results.

Line 377 and further: In how many of the children with at least one positive isolates, positive isolates were also found in animals?

Line 388: how were the 200 additional isolates selected?

Line 406: please delete 'all fecal samples', because you are modeling at the isolate level.

Line 419: do you mean marginally significant? Instead of marginally significant I would suggest to use the term borderline significant.

If I understood correctly, another manuscript is discussing the similarity between the isolates collected within epidemiologically linked clusters (humans and animals from the same household). The combination of an epi analysis and the isolate characteristics are telling a much fuller view on the matter. I really don't understand why this information is not used in this manuscript to support the findings.

Discussion

Line 445-449: Please delete, you don't have to summarize the study.

Line 461: Depending on the ARB/ARG, but most of the studies do not report transmission from humans with intense contact with animals to other humans. You might want to nuance this statement a bit.

469-474: Please delete, I don't see any reason to state this. It does not interpret results or highlight any finding in a broader context.

Line 543: I don't agree with your reasoning regarding your choice on what level to perform the analysis. Especially in terms of translating and interpreting the results. A risk factor for a positive isolate is less interesting, since the exposure is present (and therefore also focus for mitigation) on the individual level. And not on the isolate level. I would strongly suggest (as the other reviewers did as well) to model at the individual level and do a sensitivity level as you did with an individual outcome only based on the first isolate. Furthermore, I find the term 'some slight differences' rather vague.

Line 546: Please replace 1 by one.

Line 566-594: Although I understand the request for including implications, I find this way too long. I am sure you can describe the points you are raising in a much more concise way.

Reviewer #4: The authors have addressed most of my points but there remain a few to clear up.

I asked whether there had been a formal sample size determination but the rebuttal does not seem to mention this either way.

The authors have estimated parameters in their model page 18 "Multivariable log-binomial regression models were used to estimate unadjusted and adjusted

relative risks" so I still fail to see how they can continue to claim they used non-parametric methods and hence how these were supposed to deal with selection effects.

I am afraid I do not understand their response about Supplementary Figure S1. Either a risk factor is theoretically important in which case it belongs in S1 and in the analysis even if it fails to reach some arbitrary level of statistical significance or it is not in which case it should not appear anywhere. The authors have put household members use of antibiotics in S1 but not the analysis which is inconsistent.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Attachment

Submitted filename: Reviewers comments R2.docx

Decision Letter 3

Philippa C Dodd

28 Jul 2023

Dear Dr. Amato,

Thank you very much for re-submitting your manuscript "Risk factors for extended-spectrum beta-lactamase (ESBL) producing E. coli carriage among children in a food animal producing region of Ecuador: A repeated-measures observational study" (PMEDICINE-D-22-02768R3) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the guest editor and it was also seen again by the statistical reviewer. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.  

We look forward to receiving the revised manuscript by Aug 04 2023 11:59PM.   

Sincerely,

Philippa Dodd, MBBS MRCP PhD

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from the Guest Editors:

This study was very laborious it is very good but it has microbiological flaws. I am concerned with the microbiologic aspects of the study, especially items 4 and 5, the authors must explain these before having the manuscript accepted. They are:

1. The identification of the E. coli isolates at the species level was not confirmed by a proper methodology.

2. The authors used an outdated version of CLSI (2014) for interpreting the antimicrobial susceptibility results. There is an updated version freely available.

3. The methodology employed for confirming the ESBL phenotype. They use only ceftazidime disks combined with clavulanic acid.

4. The disproportion between the number of isolates resistant to third-generation cephalosporins and the number of isolates detected as ESBL producers. In carbapenem-susceptible isolates, the production of ESBL and/or AmpC are the main mechanisms of resistance to third-generation cephalosporins in Enterobacterales. Due to the methodology employed, many ESBL-producing isolates could have been missed. It may be true because ESBL encoding genes were detected in "ESBL negative isolates" as explained below.

5. The detection of ESBL encoding genes such as the blaCTX-M genes among isolates classified as non-ESBL producers (ESBL-negative; Table S5 and Figure S3) is a cause of concern. How do the authors justify the presence of the ESBL encoding gene and the absence of the ESBL phenotype? Were the E. coli isolates not detected as ESBL-positives because there was an association with other resistance mechanisms? Was there a lack of gene expression? The gene may not be expressed in some isolates, but it would be uncommon to a high proportion of isolates unless there is a spread of a specific clone. Could this result be justified by the methodology employed to confirm the ESBL phenotype? The authors employed ceftazidime discs combined with clavulanic acid. It would not be a problem for screening some variants of CTX-M, such as CTX-M-3 or CTX-M-15, but it would be for other variants because cefotaxime and ceftriaxone are the preferred substrates for other variants. The authors must clarify the reasons for detecting ESBL-encoding genes in ESBL-negative isolates. Do these isolates express or not these genes? If these genes are expressed, these E. coli isolates must be reclassified as ESBL-positives. The numbers would change and new analyses would be necessary.

6. The authors observed colonization of children (Table S2 - N=5) and animals (Table S3 - N=2) by E. coli resistant to imipenem. The authors did not make any comments on this. Were they really E. coli? Was this resistance phenotype confirmed? If it was, were these isolates producers of carbapenemases? It would be interesting to know if any children’s family members had been recently hospitalized.

Comments from Reviewers:

Reviewer #4: The authors have addressed my few remaining points.

Michael Dewey

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 4

Philippa C Dodd

15 Sep 2023

Dear Dr Amato, 

On behalf of my colleagues I am pleased to inform you that we have agreed to publish your manuscript "Risk factors for extended-spectrum beta-lactamase (ESBL) producing E. coli carriage among children in a food animal producing region of Ecuador: A repeated-measures observational study" (PMEDICINE-D-22-02768R4) in PLOS Medicine.

The Special Issue Guest Editor(s) raise on-going concern regarding the criteria used to classify ESBL isolates, please see the comments below. Prior to publication we require that you include a paragraph in the limitations section of your discussion detailing this as a significant limitation of your study. Please also detail this limitation in the abstract at the end of the methods and findings section and as a final point in the ‘what do these findings mean section of the author summary. We cannot proceed to publication without these additional details.

COMMENTS FROM THE GUEST EDITOR(S)

"The main issue with this manuscript is that the authors used a phenotypic test as a standard to classify the isolates as ESBL and identify the risk factors for ESBL. Even if they had tested cefotaxime disks with clavulanic acid, they might not have identified E. coli isolates that were ESBL producers associated with other resistance mechanisms, such as the production of AmpC (blaCMY-2), as they did, for example.

There is no widely accepted standard, but in my opinion, they should have considered detecting ESBL-encoding genes in third-generation cephalosporin-resistant E. coli isolates as the criterion for classifying isolates as ESBL producers and then identifying risk factors for ESBL colonization from there.

The study is wonderful, involving the efforts and work of many people, with a very thorough analysis of the results. However, it made a mistake in defining the criteria for classifying isolates as ESBL."

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.

In the meantime, please log into Editorial Manager at http://www.editorialmanager.com/pmedicine/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. 

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with medicinepress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper. 

Best wishes, 

Philippa Dodd, MBBS MRCP PhD 

PLOS Medicine

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Files. Supplementary files.

    Checklist: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist of items that should be included in reports of cohort studies. Sample Size and Power Calculations. Table A. Prevalence of third-generation cephalosporin-resistant, extended-spectrum beta-lactamase, multidrug-resistant, and extensively drug-resistant E. coli among children. Table B. Proportion of third-generation cephalosporin-resistant E. coli (3GCR-EC) isolates resistant to individual antibiotics in phenotypic susceptibility testing by data collection cycle. Table C. Antibiotic resistance of 3GCR-EC isolates from animal fecal samples (1 colony isolated per fecal sample) collected at the same households as child fecal samples, stratified by animal species. Table D. Prevalence of clinically important sequence types (ST) among sequenced 3GCR-EC isolates (N = 571) from child fecal samples. Table E. Proportion of 3GCR-EC isolates with beta-lactamase genes (among 15 most prevalent) detected in whole-genome sequences, stratified by phenotypic ESBL production. Table F. Prevalence of beta-lactamase resistance genes among sequenced 3GCR-EC isolates from children, stratified by parishes and intensity of commercial food animal production. Table G. Average number of total antibiotic resistance genes (ARGs) per third-generation cephalosporin-resistant E. coli isolate from children, stratified by parish. Table H. Prevalence of CTX-M-type genes among sequenced 3GCR-EC isolates from children, stratified by parish and intensity of commercial food animal production. Table I. Sensitivity analysis results for main analysis associations between combined food animal exposures and 3GCR-EC and ESBL-EC including only 1 isolate per child fecal sample. Table J. Associations between secondary risk factors and 3GCR-EC carriage among children. Table K. Associations between secondary risk factors and ESBL-EC carriage among children. Table L. Secular trends in caregiver-reported child illness and antibiotic use stratified by household food animal ownership. Table M. Access to water and sanitation at households included in the main analysis (N = 594). Fig A. Directed acyclic graph of causal relationship between exposures to commercial and household food animal production and ESBL-E. coli carriage in children. SES: socioeconomic status. ESBL: extended-spectrum beta-lactamase E. coli. Fig B. Flow chart of enrollment and follow-up by data collection cycle. Households were included in the final analysis if they had the necessary exposure, outcome, and covariate data. Fig C. Prevalence of beta-lactamase genes (top 15 most prevalent) among sequenced third-generation cephalosporin-resistant E. coli isolates from children, stratified by phenotypic extended-spectrum beta-lactamase (ESBL) production. Fig D. Prevalence of beta-lactamase genes by type among third-generation cephalosporin-resistant E. coli (3GCR-EC) isolated from children, stratified by parish.

    (DOCX)

    Attachment

    Submitted filename: amato.pdf

    Attachment

    Submitted filename: PLOS Medicine Reviewer Comments.docx

    Attachment

    Submitted filename: Reviewers comments R2.docx

    Attachment

    Submitted filename: PLOSMed Response to Round 2 Reviews.docx

    Attachment

    Submitted filename: Round 3 reviewer comments.docx

    Data Availability Statement

    Raw reads from isolates sequenced in this study are available at the NCBI Short Read Archive (SRA) under BioProject accession no. PRJNA861272. Exposure and outcome data used in epidemiological analyses are published and publicly available on Dryad (https://doi.org/10.5061/dryad.41ns1rnm7).


    Articles from PLOS Medicine are provided here courtesy of PLOS

    RESOURCES